Introduction {#s1}
============

Supporting vital biological functions, voltage-gated calcium (Ca~V~1 and Ca~V~2) and sodium (Na~V~1) channels are tuned by the Ca^2+^-binding protein, calmodulin (CaM) ([@bib9]; [@bib18]; [@bib87]). Na~V~1 supports action potential initiation and propagation ([@bib39]), while Ca~V~1/2 initiate muscle contraction, neurotransmission, and gene transcription ([@bib10]; [@bib20]; [@bib65]). Despite divergent functions, these channel families share a conserved carboxy-tail element, termed Ca^2+^-inactivating (CI) module, that harbors CaM. Functionally, the CI module confers dynamic Ca^2+^-dependent regulation to Ca~V~1, Ca~V~2, and Na~V~1 that manifests as either inactivation (CDI) or facilitation (CDF), negative and positive feedback, respectively ([@bib9]; [@bib67]). Yet, this modularity poses a challenge -- mechanisms that tune Ca^2+^/CaM-feedback must distinguish between structurally similar targets. Global inhibition of CaM indiscriminately alters many processes ([@bib81]). Given the abundance of CaM-regulated proteins, mechanisms that adjust CaM signaling to individual targets are crucial ([@bib66]; [@bib87]). Physiologically, Ca^2+^-regulation of Ca~V~1 is critical for cardiac electrical stability ([@bib57]; [@bib64]), rhythmicity of oscillatory neurons ([@bib19]; [@bib42]), and vesicle release at ribbon synapses ([@bib46]). Ca~V~2 modulation contributes to short-term synaptic plasticity and spatial learning ([@bib2]; [@bib44]; [@bib71]), while Na~V~1 modulation tunes excitability of skeletal and cardiac muscle ([@bib83]; [@bib102]). Consequently, aberrant channel regulation underlies numerous maladies including cardiac arrhythmias ([@bib103]; [@bib120]), neurological and neuropsychiatric disorders ([@bib1]; [@bib94]; [@bib118]), and skeletal myotonia ([@bib17]).

Src homology 3 (SH3) and cysteine-rich domain (C1) proteins (stac) have emerged as attractive candidates that modulate Ca~V~ gating and trafficking ([@bib84]; [@bib95]). Initially identified in association with congenital skeletal myopathies as a structural protein that abets Ca~V~1.1 plasmalemmal trafficking ([@bib40]; [@bib61]; [@bib84]), stac also suppresses Ca~V~1.2 CDI ([@bib15]; [@bib112]). Even so, the specificity of stac in tuning Ca^2+^-regulation of the broader Ca~V~/Na~V~ family, the underlying elementary mechanisms, and molecular determinants remain to be fully elucidated ([@bib112]). Stac isoforms (stac1-3) share a common architecture containing a C1 and two SH3 domains fused via a linker, and exhibit tissue-specific expression ([@bib95]). Stac1/2 are expressed throughout the brain ([@bib72]; [@bib95]), the peripheral nervous system ([@bib55]), the retina ([@bib111]), and the inner ear ([@bib14]), while stac3 is limited to the skeletal muscle ([@bib72]). Resolving mechanisms by which stac modulates Ca~V~ may furnish long-sought physiological insights ([@bib95]).

Evolutionarily distinct from stac, fibroblast growth factor (fgf) homologous factors (fhf1-4, fgf11-14) are unconventional fgf that lack a secretory signal and serve as intracellular regulators of Na~V~ gating and trafficking ([@bib33]; [@bib78]). Curiously, fhf interacts with the Na~V~ CI module in close proximity to the CaM binding interface, suggesting interplay between these modulators ([@bib107]; [@bib106]). Yet, functionally, fhf is thought to modulate only voltage-dependent fast inactivation ([@bib34]; [@bib63]; [@bib105]), with changes in Ca^2+^-regulation unknown. Fhf isoforms are differentially expressed in the brain ([@bib92]; [@bib115]), peripheral nervous system ([@bib76]), and cardiac ([@bib110]) and skeletal muscle ([@bib50]). Genetic variation in fhf4 is linked to spinocerebellar ataxia 27 ([@bib21]) and fhf1 to cardiac arrhythmias ([@bib110]), hinting at their relevance for regulating neuronal and cardiac excitability.

By leveraging synergistic insights from Ca~V~ and Na~V~ channels, we demonstrate that stac selectively diminishes Ca^2+^-regulation of Ca~V~1. In-depth analysis shows that stac binds to a distinct channel interface from CaM and uses an allosteric mechanism to lock Ca~V~1 into a high open probability (*P*~O~) gating mode. We further localize a minimal motif that recapitulates stac modulation of Ca~V~1 gating. Paralleling stac-effect on Ca~V~1, fhf reduces CDI of Na~V~1 with no effect on Ca~V~1. In all, our findings point to a general class of auxiliary proteins that intercept CaM signaling to individual targets, allowing spatial and temporal orchestration of Ca^2+^-feedback.

Results {#s2}
=======

Stac selectively suppresses Ca^2+^-feedback of Ca~V~1 channels {#s2-1}
--------------------------------------------------------------

We sought to determine stac effect on Ca~V~1, Ca~V~2, and Na~V~1 channels in heterologous systems. [Figure 1A](#fig1){ref-type="fig"} shows baseline effects of stac on Ca~V~1.2 ([@bib15]; [@bib84]; [@bib112]). Devoid of stac, Ca~V~1.2 exhibits CaM-mediated CDI manifesting as enhanced decay of Ca^2+^ (red) versus Ba^2+^ current (black) when elicited using a step depolarization ([Figure 1A](#fig1){ref-type="fig"}, middle subpanel). As Ba^2+^ binds CaM poorly ([@bib58]), Ba^2+^-currents furnish a baseline measure of voltage-dependent inactivation (VDI) without CDI. Upon stac2 co-expression, CDI is diminished ([Figure 1A](#fig1){ref-type="fig"}, right subpanel). To quantify steady-state extent of inactivation, we measured the fraction of peak Ca^2+^ and Ba^2+^ current remaining after 300 ms depolarization, *r*~Ca~ and *r*~Ba~ ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). The strength of CDI is quantified as *CDI*~300~ = 1 -- *r*~Ca~/*r*~Ba~, the fractional Ca^2+^-dependent component of inactivation. Thus quantified, the population data confirm a reduction in CDI of Ca~V~1.2 with stac2 (p=3.6 × 10^−5^; [Figure 1B](#fig1){ref-type="fig"}). Further analysis shows that both stac1 and stac3 isoforms also diminish CDI (p=2.0 × 10^−5^ and 7.1 × 10^−5^, respectively, [Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Similarly, Ca~V~1.3 short variant (Ca~V~1.3~S~), a close homolog of Ca~V~1.2, exhibits strong baseline CDI that is reduced on co-expression of stac1, stac2, and stac3 (p\<1 × 10^−5^; [Figure 1C--D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Generalizing this phenomenon, stac2 also reduces CDI of Ca~V~1.4~43\*~ (p=3.2 × 10^−5^; [Figure 1E--F](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) ([@bib97]).

![Stac specifically abolishes Ca^2+^/CaM-regulation in Ca~V~1 channels.\
(**A**) Stac2 diminishes CDI of Ca~V~1.2. Left, cartoon schematic shows Ca~V~1.2. Middle, exemplar current traces evoked in response to +10 mV voltage-step shows robust CDI (rose shaded area) evident as enhanced current decay with Ca^2+^ (red) versus Ba^2+^ (black) as the charge carrier. Right, stac2 abolishes CDI. Steady-state levels of inactivation are assessed as the fraction of peak current remaining following 300 ms depolarization (*r*~Ca~ and *r*~Ba~) and CDI = 1 -- *r*~Ca~/*r*~Ba~. (**B**) Bar graph displays population data of CDI~300~ for Ca~V~1.2 in the absence and in the presence of stac1, stac2, or stac3. Dashed line shows baseline CDI in the absence of stac for comparison. Each bar, mean ±S.E.M. obtained from specified number of cells (n). (**C--D**) Stac isoforms suppress CDI of Ca~V~1.3~S~, the canonical short variant, as confirmed by both exemplar traces (**C**) and population data (**D**). Format as in (**A**) and (**B**). (**E--F**) Stac2 abolishes CDI of Ca~V~1.4~43\*~ assessed in response to +20 mV test pulse. Format as in (**A**) and (**B**). (**G--H**) Stac2 spares CDF of Ca~V~2.1, as evaluated using a prepulse protocol. An isolated test pulse to 0 mV elicits Ca^2+^ currents with biphasic activation (gray, **G**). With a + 20 mV prepulse, channels are partially facilitated and the slow component of activation is reduced (red, **G**). The area between the two current traces (*ΔQ*), divided by *τ*~slow~, yields facilitation (g). Bar graph plots, CDF = *g*~Ca~ -- *g*~Ba~**H**). Each bar, mean ±S.E.M from specified number of cells (n). (**I--J**) Stac2 spares CDI of Ca~V~2.2 assessed in response to +30 mV test pulse. Here, CDI is evaluated following 800 ms of depolarization to accommodate slow inactivation kinetics, yielding CDI~800~. Format as in (**A**) and (**B**). (**K--L**) Stac2 spares CDI of Ca~V~2.3. Format as in (**A**) and (**B**). (**M--N**) Stac2 spares CDI of Na~V~1.4. Both in the absence and presence of stac, Na~V~1.4 peak currents decline following a Ca^2+^ step (rose fit) (**M**). Gray dots, peak currents before uncaging. CDI = 1 -- average peak *I*~Na~ of last three to four responses after Ca^2+^ uncaging / peak *I*~Na~ before uncaging. Bar graph plots maximal CDI observed with Ca^2+^ steps \> 5 μM (**N**). Each bar, mean ±S.E.M.](elife-35222-fig1){#fig1}

Encouraged by its pervasiveness, we considered whether stac alters Ca^2+^-dependent modulation of Ca~V~2 isoforms that are abundant in the central nervous system. For Ca~V~2.1, CaM elaborates both CDF and CDI ([@bib24]; [@bib52]). However, the Ca^2+^-sensitivity of CDI process is over 50-fold weaker than that of CDF, casting this negative feedback beyond physiological bounds ([@bib54]). As such, we probed whether stac tunes CDF of Ca~V~2.1 using a well-established prepulse protocol ([@bib24]; [@bib99]). [Figure 1G](#fig1){ref-type="fig"} displays wildtype Ca~V~2.1 currents in the absence of stac2. On presentation of an isolated test pulse to 0 mV, the activation of Ca^2+^ current follows a biphasic response (gray trace). Following a brief voltage prepulse, however, the ensuing test pulse yields enhanced Ca^2+^-currents with monophasic activation reflecting CDF (red trace). Further quantification revealed no change in CDF of Ca~V~2.1 following the addition of stac2 in both exemplar current recordings ([Figure 1G](#fig1){ref-type="fig"}) and population data ([Figure 1H](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). For Ca~V~2.2, CaM-regulation manifests as a kinetically slow CDI ([Figure 1I](#fig1){ref-type="fig"}) ([@bib56]), that persists despite stac co-expression ([Figure 1I--J](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Here CDI is quantified by metric CDI~800~ = 1 -- *r*~Ca~/*r*~Ba~, measured following 800 ms of depolarization. Likewise, neuronal Ca~V~2.3 also possesses robust CDI, which is spared with stac2 co-expression ([Figure 1Figure 1K--L](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}).

Lastly, we tested whether stac suppresses Ca^2+^-regulation of Na~V~1, related to Ca~V~1. Although all Na~V~1 possess a CI module homologous to both Ca~V~1 and Ca~V~2 ([@bib5]), CDI that bears mechanistic similarity to Ca~V~ has been identified only in Na~V~1.4 ([@bib8]). Unlike Ca~V~, Na~V~ channels do not convey Ca^2+^ influx that triggers Ca^2+^-feedback. We used rapid photo-uncaging of Ca^2+^ to produce a step-like increase in intracellular \[Ca^2+^\]~i~, whose magnitude is simultaneously monitored via fluorescent indicators. [Figure 1M](#fig1){ref-type="fig"} displays baseline Ca^2+^-regulation of Na~V~1.4. As CDI is kinetically slow in comparison to fast inactivation, we applied a train of step depolarizations evoked at 10 Hz to probe Ca^2+^-dependent effects ([@bib8]). Without Ca^2+^-uncaging, peak Na~V~1.4 currents remained steady (gray dots). In response to an \~10 μM Ca^2+^ step, the peak Na current declined rapidly revealing CDI (red envelope). Stac overexpression, however, does not disrupt Na~V~1.4 CDI ([Figure 1M--N](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}). Overall, these results show the specificity of stac in tuning Ca^2+^-regulation of Ca~V~1 channels.

Stac interacts with Ca~V~1 CI module to elicit CDI suppression {#s2-2}
--------------------------------------------------------------

We sought to identify molecular mechanisms that underlie selective Ca~V~1 modulation by stac. As the stac effect here is inferred based on overexpression analysis, we determined relative concentration requirements for stac binding to Ca~V~1 holo-channel complexes within the milieu of living cells. We used live cell FRET 2-hybrid assay ([@bib29]) to probe the interaction of CFP-tagged stac3 with YFP-linked Ca~V~1.3~S~. As all three stac variants suppress the CDI of all Ca~V~1 isoforms, we chose Ca~V~1.3 as YFP-tethered channels and a repertoire of YFP-tagged intracellular loop peptides are readily available for in-depth binding analysis ([@bib117]). Stac3 was selected for its high potency in suppressing Ca~V~1.3 CDI ([Figure 1D](#fig1){ref-type="fig"}). Accordingly, we quantified FRET efficiency (*E*~D~) between FRET pairs co-expressed in individual cells. By leveraging stochastic expression of the FRET pairs in cells, we obtained a saturating Langmuir relationship between *E*~D~ and the free acceptor concentration (*A*~free~) permitting estimation of relative binding affinities (*K*~d,EFF~). Thus probed, we obtained a Ca~V~1.3 holo-channel affinity for stac3 of *K*~d,EFF~ = 1458 ± 251 *D*~free~ units proportional to \~47 nM ([Figure 2A](#fig2){ref-type="fig"}). By comparison, similar analysis of CaM binding to Ca~V~1.3 showed *K*~d,EFF~ = 700 *D*~free~units \~ 22 nM ([@bib117]). Consequently, stac's relatively high binding-affinity for Ca~V~1.3 suggests that it may be a potent modulator even at low concentrations.

![Stac interacts with the channel carboxy-terminus.\
(**A**) Live-cell FRET 2-hybrid assay shows high-affinity interaction between CFP-tagged stac3 with YFP-tethered holo-Ca~V~1.3 channels in the presence of auxiliary β~2A~ and α~2~δ subunits. (**B**) Cartoon shows FRET pairs, CFP-stac3 with YFP-CI, YFP-PCI, and YFP-IQ of Ca~V~1.3. (**C**) FRET-binding curves show robust binding of stac3 to both the CI and PCI segment while binding to IQ is weaker. (**D**) Bar graph summarizes the relative association constant, *K*~a,EFF~, of stac2 binding to major channel intracellular domains. (**E--F**) Transferring Ca~V~1.3~S~ CI to Ca~V~2.3 (Ca~V~2.3/1.3 CI) unveils latent stac2-mediated suppression of CDI. Format as in [Figure 1A](#fig1){ref-type="fig"} -- B.](elife-35222-fig2){#fig2}

With holo-channel binding assured, we systematically scanned YFP-tagged Ca~V~1.3 intracellular domains ([@bib117]) for stac binding sites ([Figure 2B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). We found that stac3 binds well to the CI region (*K*~d,EFF~ = 20697 ± 3023 *D*~free~\~0.67 ± 0.1 μM, [Figure 2C](#fig2){ref-type="fig"}). By contrast, analysis of the amino-terminus, intracellular loops between domains I and II (I-II loop), domains II and III (II-III loop), and domains III and IV (III-IV loop) revealed far weaker binding ([Figure 2D](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1B--E](#fig2s1){ref-type="fig"}). To further localize the putative binding loci, we subdivided the CI module into two: (1) a proximal CI segment (PCI) composed of dual vestigial EF hand and preIQ segments and (2) the IQ domain (IQ). The YFP-tagged PCI segment bound stac3 with approximately tenfold higher affinity (*K*~d,EFF~ = 17725 ± 3990 *D*~free~\~0.58 ± 0.1 μM) than the downstream IQ domain (*K*~d,EFF~ = 204739 ± 25465 *D*~free~\~6.67 ± 0.8 μM) ([Figure 2C--D](#fig2){ref-type="fig"}). In all, systematic FRET analysis reveals that stac binds to Ca~V~1 CI relying on upstream elements including the dual vestigial EF hand and preIQ domains, an interface distinct from that for CaM ([@bib6]; [@bib67]).

To test for functional relevance of stac binding to the Ca~V~1 CI module, we sought to confer stac-sensitivity to a stac-insensitive channel via a chimeric approach. We turned to Ca~V~2.3 that lacks strong stac-mediated CDI suppression, yet forms functional chimeras with Ca~V~1 ([@bib70]; [@bib117]). We replaced the CI region of Ca~V~2.3 with the corresponding segment from Ca~V~1.3 (Ca~V~2.3/1.3 CI). Devoid of stac, Ca~V~2.3--1.3 CI channels exhibit CDI isolated by high intracellular buffering ([Figure 2E--F](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). In contrast to wildtype Ca~V~2.3, stac2 co-expression attenuated CDI (p=4.7 × 10^−4^, [Figure 2E--F](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}), suggesting that Ca~V~1 CI module is necessary for stac-mediated CDI suppression.

Stac uses an allosteric mechanism to suppresses CaM signaling {#s2-3}
-------------------------------------------------------------

Given that both CaM and stac share the CI module as an effector site, two disparate mechanistic possibilities may allow suppression of Ca^2+^-regulation. First, stac may competitively displace Ca^2+^-free CaM (apoCaM) from its preassociation site. Second, stac may supersede CaM signaling to the channel pore via an allosteric mechanism. Systematic FRET analysis suggests that stac preferentially binds upstream CI elements ([Figure 2D](#fig2){ref-type="fig"}) while high-affinity CaM preassociation is supported via the IQ domain ([@bib6]; [@bib67]), hinting that the two modulatory proteins may bind concurrently. To rule out competitive displacement of CaM preassociation, we covalently tethered CaM onto the Ca~V~1.3 carboxy-tail using a poly-glycine linker (Ca~V~1.3~S~-CaM) ([@bib69]; [@bib117]). This maneuver preserves CDI ([Figure 3A](#fig3){ref-type="fig"} left) and ensures a high local CaM concentration near Ca~V~1 extending into the millimolar range, sufficient to protect the channel from a competitive inhibitor ([@bib69]). Dominant-negative CaM~1234~ with its Ca^2+^-binding sites disabled, typically displaces intact apoCaM from the CI module thereby resulting in a loss of CDI for wildtype channels ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}) ([@bib117]). CDI of Ca~V~1.3~S~-CaM persists despite CaM~1234~ co-expression (gray bar, [Figure 3B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1C--D](#fig3s1){ref-type="fig"}). By contrast, CDI of Ca~V~1.3~S~-CaM is diminished by co-expression of stac2 (p=3.8 × 10^−6^, [Figure 3A--B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}) and stac3 (p=4.5 × 10^−4^, [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). As a further test, co-expression of untethered Ca~V~1.3~S~ with both CaM and stac2 also showed low CDI ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). We observed a similar fate for Ca~V~1.2-CaM with stac2 (p=1.5 × 10^−5^, [Figure 3C--D](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}). These findings suggest that stac does not need to dislodge CaM from its Ca~V~1.3 carboxy-tail binding interface to exert functional modulation.

![Allosteric regulation of stac by interaction with the channel carboxy-terminus.\
(**A--B**) Stac2 suppresses CDI of Ca~V~1.3~S~ tethered to CaM. In contrast, fusion of CaM protects Ca~V~1.3~S~ from competitive inhibitors such as CaM~1234~. Format as in [Figure 1A--B](#fig1){ref-type="fig"}. (**C--D**) Stac2 suppresses CDI of Ca~V~1.2 tethered to CaM. Format as in [Figure 1A--B](#fig1){ref-type="fig"}. (**E**) FRET 2-hybrid assay shows the high-affinity interaction of YFP-tagged Ca~V~1.3 CI to CFP-tagged CaM with relative dissociation constant *K*~d,EFF~ \~4000 ± 291 *D*~free~ units. (**F**) Co-expression of untagged CaM~1234~ with FRET pairs YFP-tagged Ca~V~1.3 CI and CFP-tagged CaM results in a marked reduction in FRET efficiency. (**G**) Co-expression of untagged stac3 spares the binding of YFP-tagged Ca~V~1.3 CI with CFP-tagged CaM, yielding an identical *E*~A~-*D*~free~ relationship to that in the absence of stac3 (**E**).](elife-35222-fig3){#fig3}

To test this possibility, we undertook FRET 2-hybrid assay comparing binding of CFP-tagged CaM to YFP-tagged Ca~V~1.3 CI in the presence and absence of unlabeled stac3. If stac3 were to competitively dislodge CaM, then this binding is predicted to be weakened. At baseline, CaM binds to Ca~V~1.3 CI with a relative dissociation constant, *K*~d,EFF~ \~4000 ± 291 *D*~free~ units ([Figure 3E](#fig3){ref-type="fig"}) ([@bib7]). Upon co-expression of CaM~1234~, this baseline binding is weakened \~11 fold, yielding a relative affinity of 47153 ± 4815 *D*~free~ units ([Figure 3F](#fig3){ref-type="fig"}). By contrast, co-expression of stac3 did not appreciably perturb CaM binding to the CI module with *K*~d,EFF~ = 4182 ± 330 *D*~free~ units ([Figure 3G](#fig3){ref-type="fig"}). These results suggest that both stac and CaM act concurrently via distinct sites on the channel carboxy-tail, in contradiction with a competitive mechanism.

Elementary mechanisms underlying stac-regulation of Ca~V~1 {#s2-4}
----------------------------------------------------------

Beyond Ca^2+^-dependent regulation, apoCaM binding tunes the baseline activity of Ca~V~ channels ([@bib3]). Absent stac, Ca~V~1 lacking prebound CaM adopts a low *P*~O~ configuration (empty configuration, *P*~O/E~) while apoCaM binding switches channels into a high *P*~O~ mode (CaM-bound configuration, *P*~O/A~) ([@bib3]). Ca^2+^/CaM divests this initial enhancement in *P*~O~ and returns channels into a low *P*~O~ gating mode (*P*~O/E~) manifesting as CDI. The addition of stac as a regulatory agent enriches this modulatory scheme ([Figure 4A](#fig4){ref-type="fig"}). Three distinct scenarios may underlie suppression of Ca^2+^-regulation by stac ([Figure 4B](#fig4){ref-type="fig"}): (1) stac binding may pre-inhibit channels into the low *P*~O~ configuration (*P*~O/E~) akin to Ca^2+^-inactivated channels and prevent further Ca^2+^-modulation, (2) stac may obstruct Ca^2+^/CaM regulation while allowing apoCaM to change baseline *P*~O~, (3) stac binding may allosterically lock channels into a high *P*~O~ mode irrespective of CaM-binding status. For Scenario 3, it is possible that the baseline *P*~O~ of Ca~V~1.3 with stac may be distinct from that observed with CaM-overexpression. These three scenarios may be distinguished at the single-molecule level by assessing Ca~V~1 *P*~O~ under various CaM-bound conditions using low-noise electrophysiology. We focused on Ca~V~1.3 given the rich assortment of post-transcriptionally modified variants with distinct CaM binding affinities ([@bib6]; [@bib62]; [@bib91]). We focused on three variants, Ca~V~1.3~S~ with high apoCaM affinity, and Ca~V~1.3~MQDY~ and Ca~V~1.3~L~ with low affinities. These variants possess distinct baseline *P*~O~ and CDI and constitute a convenient platform to identify stac-dependent effects ([@bib3]; [@bib96]).

![Stac enhances the *P*~O~ of Ca~V~1.3.\
(**A**) A general four-state scheme for stac and CaM modulation. (1) Ca~V~1.3~S~ devoid of CaM and stac possess a low baseline *P*~O~ (*P*~O/E~). (2) Without stac, apoCaM binding to Ca~V~1.3~S~ upregulates baseline *P*~O~ (*P*~O/A~). Baseline *P*~O~ of Ca~V~1.3~S~ bound to stac in the absence (configuration 3, *P*~O/E\*~) and the presence of apoCaM (configuration 4, *P*~O/A\*~) are unknown. (**B**) Schematic outlines three mechanistic possibilities for stac binding to Ca~V~1 and their functional outcomes. Scenario 1, stac uniformly suppresses *P*~O~ of Ca~V~1 (*P*~O/E~) and abolishes CDI. Scenario 2, apoCaM tunes baseline *P*~O~ of Ca~V~1 despite concurrent stac binding. Stac, nonetheless, abrogates CDI. Scenario 3, stac uniformly upregulates the baseline *P*~O~ of Ca~V~1 and abolishes CDI (*P*~O/A~). (**C**) Top, cartoon shows the canonical Ca~V~1.3~S~ variant with a high apoCaM binding affinity. Single-channel analysis of recombinant Ca~V~1.3~S~ in the absence (middle) and presence of stac (bottom). In both panels, the unitary Ba^2+^ currents during voltage-ramp are shown between −50 mV and +40 mV (slanted gray lines, GHK fit). Robust Ca~V~1.3 openings are detected in the absence and presence of stac. (**D**) Average single-channel *P*~O~-voltage relationship for Ca~V~1.3~S~ obtained from multiple patches in the absence (gray) and presence of stac2 (blue). Error bars indicate ±S.E.M. for specified number of patches and 80--150 stochastic records per patch. (**E**) Histogram shows distribution of single-trial average *P*~O~ ($\overset{-}{P}$~O~) for the voltage range -30 mV ≤ *V* ≤ +25 mV under control (top), stac-bound (middle), and CaM-bound (bottom) conditions. $\overset{-}{P}$~O~-distribution is bimodal in the absence of stac corresponding to high *P*~O~ (gray) and low *P*~O~ (rose) gating modes. With stac, $\overset{-}{P}$~O~-distribution is largely restricted to the high *P*~O~ mode. (**F--H**) Single-channel analysis of a recombinant Ca~V~1.3~RNA-edited~ variant reveals a marked upregulation in the baseline *P*~O~ in the presence of stac compared with control conditions in which apoCaM preassociation is weak. Absent stac or CaM, single-trial $\overset{-}{P}$~O~-distribution is restricted to the low *P*~O~ limits, With either stac or CaM, the high *P*~O~ gating mode re-emerges. Format as in (**C--E**). (**I--K**) Stac also upregulates the baseline *P*~O~ of Ca~V~1.3~L~, an alternatively spliced variant, by stabilizing the high *P*~O~ gating configuration. Format as in (**C--E**).](elife-35222-fig4){#fig4}

First, we analyzed Ca~V~1.3~S~ in the presence and absence of stac ([Figure 4C--E](#fig4){ref-type="fig"}) to determine whether stac may promote channel entry into a low *P*~O~ gating configuration. Ca~V~1.3~S~ is typically prebound to CaM at endogenous CaM concentrations given its high affinity ([@bib3]). Ba^2+^ is used as a charge carrier to estimate baseline behavior of channels without confounding effects of CDI. A slow voltage-ramp (shown between −50 and +40 mV) evokes stochastic channel openings that approximate near steady-state *P*~O~ at each voltage. Stochastic records displayed in [Figure 4C](#fig4){ref-type="fig"} show channel openings as downward deflections to the open level (gray curves) and closures correspond to the zero-current portions of the trace. Robust openings are detected both in the presence and absence of stac ([Figure 4C](#fig4){ref-type="fig"}). To estimate the steady-state *P*~O~ -- voltage relationship, we averaged many stochastic records to obtain a mean current that is divided into the open level and averaged over multiple patches. Ca~V~1.3~S~ variant exhibits high *P*~O~ in the absence of stac ([Figure 4D](#fig4){ref-type="fig"}) ([@bib3]). Upon stac2 co-expression, the open probability remains high with \~10 mV hyperpolarizing shift in the voltage-dependence of activation ([Figure 4D](#fig4){ref-type="fig"}). We scrutinized single-channel trials to assess changes in gating modes. [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} displays 10 sequential trials of Ca~V~1.3 single-channel activity evoked by voltage-ramps introduced at 12 s intervals both in the presence and absence of stac. In the absence of stac, Ca~V~1.3~S~ activity switches between epochs of high and low activity, as evident from the diary plot of average *P*~O~ within individual trials (${\overline{\mathit{P}}}_{o}$) ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Analysis of single-trial ${\overline{P}}_{o}$ distribution reveals a bimodal distribution denoting discrete high and low *P*~O~ gating modes ([Figure 4E](#fig4){ref-type="fig"}). Upon stac overexpression, channel activity is high as evident from ${\overline{P}}_{o}$-diary plots ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}) and single-trial ${\overline{\mathit{P}}}_{o}$ distribution ([Figure 4E](#fig4){ref-type="fig"}). In contradiction with Scenario 1, stac-bound channels are not pre-inhibited; rather, channels preferentially adopt a high *P*~O~ mode.

To distinguish between the second and third mechanistic possibilities, we considered Ca~V~1.3 variants with weakened apoCaM binding affinity that largely reside in the low *P*~O~ configuration ([@bib3]). Accordingly, we tested the baseline *P*~O~ of Ca~V~1.3~MQDY~, an RNA-edited variant whose central isoleucine within the IQ domain is substituted to a methionine, ([@bib6]; [@bib42]) and an alternative splice variant Ca~V~1.3~L~ containing an autoinhibitory domain that competitively displaces CaM ([@bib62]; [@bib91]). In the absence of stac and under endogenous CaM levels, both Ca~V~1.3~MQDY~ ([Figure 4F--G](#fig4){ref-type="fig"}) and Ca~V~1.3~L~ ([Figure 4I--J](#fig4){ref-type="fig"}) open sparsely, exhibiting a diminished maximal *P*~O~ consistent with channels lacking CaM ([@bib3]; [@bib11]). Indeed, single-channel trials of Ca~V~1.3~MQDY~ ([Figure 4---figure supplement 2A--C](#fig4s2){ref-type="fig"}) and Ca~V~1.3~L~ ([Figure 4---figure supplement 3A--C](#fig4s3){ref-type="fig"}) under endogenous levels of CaM reveal uniformly low activity, with single-trial *P̄*~O~ distribution restricted to low limits ([Figure 4H](#fig4){ref-type="fig"} for Ca~V~1.3~MQDY~; [Figure 4K](#fig4){ref-type="fig"} for Ca~V~1.3~L~). CaM overexpression with both channel variants reveals the resurgence of epochs of high activity ([Figure 4---figure supplement 2D--E](#fig4s2){ref-type="fig"}; [Figure 4---figure supplement 3D--E](#fig4s3){ref-type="fig"}) and a bimodal *P̄*~O~ distribution with a substantial fraction of trials corresponding to a high *P*~O~ configuration ([Figure 4H and K](#fig4){ref-type="fig"} for Ca~V~1.3~MQDY~ and Ca~V~1.3~L~ respectively). Upon stac co-expression, robust channel openings re-emerge for both Ca~V~1.3~MQDY~ ([Figure 4F--G](#fig4){ref-type="fig"}) and Ca~V~1.3~L~ ([Figure 4I--J](#fig4){ref-type="fig"}) yielding an enhanced baseline *P*~O~ akin to Ca~V~1.3~S~ variant ([@bib3]). Scrutiny of single-channel trials for both channel variants reveal uniformly high channel activity ([Figure 4---figure supplement 2F--G](#fig4s2){ref-type="fig"} for Ca~V~1.3~MQDY~; [Figure 4---figure supplement 3F--G](#fig4s3){ref-type="fig"} for Ca~V~1.3~L~) and single-trial *P̄*~O~ distributions are now within the high activity limits ([Figure 4H and K](#fig4){ref-type="fig"}) reminiscent of the CaM overexpression. The steady-state *P*~O~-*V* relations for Ca~V~1.3~S~, Ca~V~1.3~MQDY~, and Ca~V~1.3~L~ in the presence of stac closely approximate each other ([Figures 4D, G and J](#fig4){ref-type="fig"}). These findings demonstrate that consistent with Scenario 3, stac-binding locks Ca~V~1.3 channels in the high *P*~O~ configuration and effectively decouples the channel pore from CaM-dependent conformational changes. Moreover, these results highlight the dominance of stac over CaM in Ca~V~1 modulation.

U-domain constitutes a minimal motif for Ca~V~1 CDI suppression {#s2-5}
---------------------------------------------------------------

With elementary mechanisms discerned, we turned to identify stac motifs functionally critical for allosteric suppression of CaM-regulation. Structurally, stac isoforms share a modular architecture composed of a C1 domain linked to two SH3 domains via a largely unstructured linker segment (U-linker region) ([@bib95]). As these modular subcomponents typically recognize distinct ligands, we reasoned that their molecular functions may be separable ([@bib22]; [@bib23]). We trisected stac2 to assess whether individual subcomponents can recapitulate functional regulation. We focused initially on C1 and tandem SH3 domains as these segments were recently shown to be critical for Ca~V~1.1 binding and triadic localization in skeletal muscle ([@bib16]; [@bib112]). Co-expression of either segment, however, only minimally perturbed CDI of Ca~V~1.2-CaM ([Figures 5A, C and D](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A--1C](#fig5s1){ref-type="fig"}). By contrast, the linker region by itself fully abolished CDI of these channels (p=8.9 × 10^−6^, [Figure 5B and D](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}), recapitulating the effect of stac2 on Ca~V~1.2.

![Stac U-domain is a minimal effect domain for suppression of Ca~V~1 CDI.\
(**A--C**) To localize an effector motif for stac2, CDI of Ca~V~1.2-CaM was quantified in the presence of three stac subdomains: (1) C1, (2) linker region, and (3) SH3-SH3. Exemplar traces in response to a +10 mV voltage-step depolarization show robust CDI of Ca~V~1.2-CaM in the presence of C1 (**A**), and SH3-SH3 (**C**) domains. Co-expression of the linker-region is sufficient to suppress CDI of Ca~V~1.2-CaM (**B**). Format as in [Figure 1A](#fig1){ref-type="fig"}. (**D**) Bar graph summarizes population data for Ca~V~1.2-CaM CDI in the presence of the three stac subdomains. Each bar, mean ±S.E.M of CDI~300~ at +10 mV from specified number of cells. CDI levels in the presence (solid blue line) and absence (dashed gray line) of full-length stac2 is reproduced for comparison. (**E**) Bar graph shows degree of conservation for the linker region across 770 orthologs of stac2. A well conserved subsegment termed U-domain is shaded blue. (**F--G**) Co-expression of U-domain is sufficient to abolish CDI of Ca~V~1.2-CaM (**F**) and Ca~V~1.3-CaM (**G**). Format as in [Figure 1A](#fig1){ref-type="fig"}. (**H**) Bar graph displays population data for CDI of Ca~V~1.2-CaM and Ca~V~1.3-CaM in the presence of U-domain. Each bar, mean ±S.E.M of CDI~300~ at +10 mV from specified number of cells. Dashed line, baseline CDI for both channels in the absence of stac2. Blue line, CDI of both channels in the presence of full-length stac2. (**I**) Systematic alanine scanning mutagenesis of the U-domain reveals critical determinants for stac-mediated suppression of Ca~V~1.2 CDI. For comparison, Ca~V~1.2 CDI in the presence (blue line) and absence (black dashed line) of stac2 are shown. Stac2 mutants ~200~KVD/AAA, ~203~PVY/AAA, ~206~ETL/AAA fully abolish stac2-mediated CDI suppression. (**J**) Exemplar currents show that stac2 mutant ~206~ETL/AAA eliminates stac's ability to suppress Ca~V~1.2 CDI. Format as in [Figure 1A](#fig1){ref-type="fig"}. (**K**) Stac2 ~206~ETL/AAA also fails to inhibit CDI of Ca~V~1.3~S~. Format as in [Figure 1A](#fig1){ref-type="fig"}.](elife-35222-fig5){#fig5}

To localize functional segments within the U-linker, we undertook bioinformatic analysis to identify highly conserved regions. We performed multiple sequence alignment of complete sequences of 770 stac orthologs using the MUSCLE algorithm ([@bib28]) and subsequently computed an empirical measure for the degree of protein sequence conservation at each position. The degree of conservation is defined as the likelihood of observing the consensus residue at each sequence position divided by the number of distinct residues observed at this position. By this algorithm, perfectly conserved residues will yield a unitary value, whereas poorly conserved residues will have a lower score. We identified a 22-amino acid stretch, termed the U-domain ('unknown' domain), exhibiting high conservation ([Figure 5E](#fig5){ref-type="fig"}, blue shaded region). Co-expression of U-domain diminishes CDI of both Ca~V~1.2-CaM and Ca~V~1.3-CaM ([Figure 5F--H](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1E--G](#fig5s1){ref-type="fig"}). Thus informed, we undertook systematic alanine scanning mutagenesis of the stac2 U-domain to identify key residues ([Figure 5I](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Co-expression of mutant stac2 with triple alanine substitution of residues ETL\[206-208\] resulted in minimal disruption of Ca~V~1.2 and Ca~V~1.3 CDI ([Figure 5J--K](#fig5){ref-type="fig"}), suggesting that these residues are necessary. Further analysis revealed residues PVY\[203-205\] and KVD\[200-202\] to be critical for stac function ([Figure 5I](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2A--2C](#fig5s2){ref-type="fig"}). Residues outside these loci minimally affected stac modulation of Ca~V~1 ([Figure 5I](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2D--G](#fig5s2){ref-type="fig"}). These findings confirm the necessity and sufficiency of U-domain as a minimal motif for preventing CaM-regulation of Ca~V~1.

U-domain modulates native Ca~V~1 and reshapes cardiac action potentials {#s2-6}
-----------------------------------------------------------------------

Having identified a minimal U-domain for CDI suppression, we sought to assess potential physiological consequences of stac regulation in cardiac myocytes. As stac expression is yet to be identified in myocytes, we first probed its presence using immunohistochemistry with stac1- and stac2-specific antibodies. To ensure that the two antibodies reliably probe the two isoforms, we first evaluated the ability to detect stac isoforms exogenously expressed in HEK293 cells ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Untransfected cells show minimal stac1 and stac2 immunostaining ([Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}), as confirmed by confocal imaging and population data. By contrast, immunostaining with stac1 antibody shows labeling with cells expressing stac1 but not stac2 or stac3. Similarly, labeling with stac2 antibody reveals substantial fluorescence (*F* \> 300) in cells transfected with stac2 but not stac1 or stac3. Thus informed, we assessed expression and localization of stac isoforms in cardiac myocytes ([Figure 6---figure supplement 1C--F](#fig6s1){ref-type="fig"}). Analysis of acutely dissociated adult guinea pig ventricular myocytes (aGPVMs) showed stac2 labeling but not stac1 ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Consistent with these findings, immunoblotting with stac2 antibody showed \~50 kDa signal in stac2-transfected HEK293 cells but absent from untransfected cells, confirming the ability of the antibody to detect stac2 ([Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}). Analysis of aGPVM lysate revealed likely endogenous stac2 with a similar molecular weight to that of recombinant stac2 in HEK293 cells ([Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}).

Given this baseline expression, we next considered potential effects of fluctuations in ambient stac levels. We synthesized the U-domain of stac2 as a peptide and delivered it via pipette dialysis to acutely elevate the myocyte's cytosolic concentration. We validated the synthesized peptide by testing its effect on recombinant Ca~V~1.2 expressed in HEK293 cells ([Figure 6A](#fig6){ref-type="fig"}). Following pipette dialysis of the U-peptide, CDI of Ca~V~1.2 was reduced as evident from exemplar currents and population data ([Figure 6B--C](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2A--B](#fig6s2){ref-type="fig"}). Thus affirmed, we isolated ventricular myocytes from adult guinea pigs (aGPVMs) to probe changes in CDI of native Ca~V~ channels and action potential duration in response to changes in stac levels ([Figure 6D](#fig6){ref-type="fig"}). Devoid of U-domain peptide, endogenous Ca^2+^ currents in ventricular myocytes displayed CDI, establishing baseline levels of CaM-regulation ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2D](#fig6s2){ref-type="fig"}). Pipette dialysis of U-peptide reduced CDI in myocytes ([Figure 6E--F](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2E](#fig6s2){ref-type="fig"}). The reduction in overall inactivation of Ca^2+^ currents suggest that fluctuations in stac levels may markedly alter action potential waveforms. To test this possibility, we obtained current-clamp recordings of aGPVMs and compared action potential waveforms in the presence and absence of U-peptide. [Figure 6G](#fig6){ref-type="fig"} shows typical voltage profiles of action potentials in aGPVMs paced at 0.5 Hz. Waveforms are stable between traces and the mean action potential duration (*APD*~80~), the duration of time when the action potential is at least 80% of its peak voltage, is 277.9 ± 31.37 ms (mean ±S.E.M., n = 6). [Figure 6H](#fig6){ref-type="fig"} displays the complement of the cumulative distribution of *APD*~80~. When the peptide is added to the internal solution, *APD*~80~ is enhanced to 740.1 ± 105.49 ms (n = 6) ([Figure 6G--H](#fig6){ref-type="fig"}). Thus, the U-peptide both alters the CDI of endogenous cardiac Ca~V~1, prolongs APD, and may ultimately destabilize rhythmicity of the heart.

![Synthetic U-domain peptide is sufficient for physiological perturbations.\
(**A**) Schematic illustrates pipette dialysis of custom synthesized U-domain peptide in Ca~V~1.2 heterologously expressed in HEK293 cells, a strategy that emulates acute elevation of cytosolic stac2 levels. (**B--C**) Exemplar traces and population data confirm that pipette dialysis of U-domain suppresses CDI of recombinant Ca~V~1.2 in HEK293 cells. Format as in [Figure 1A--B](#fig1){ref-type="fig"}. Control relation in (**C**) is duplicated from [Figure 1B](#fig1){ref-type="fig"}. (**D--F**) Pipette dialysis of U-domain abolishes CDI of endogenous L-type current in freshly dissociated ventricular myocytes from adult guinea pigs as evident from exemplar traces and bar graph summary of population data. To eliminate T-type current, the cells were depolarized to −40 mV for a period of 100 ms. Format as in (**A---C**). (**G**) Exemplar action potential traces of aGPVMs paced at 0.5 Hz with (blue) and without (black) 0.5 μM U-domain in the internal solution. In the presence of U-domain, the action potentials are markedly prolonged (blue shaded area) consistent with a loss of CDI of native L-type current. (**H**) Complement of cumulative distribution (*P*(*APD*~80~ \>*t*) of action potential durations (*APD*~80~) obtained in the presence (blue) and absence (black) of U-domain in the internal solution.](elife-35222-fig6){#fig6}

Fhf selectively abrogate CaM signaling to Na~V~1 {#s2-7}
------------------------------------------------

Encouraged by the selectivity of stac for Ca~V~1, we sought to identify other regulatory proteins that may tune CaM-signaling to related channel families. However, recognizing such modulators amidst ion channel signalosomes is challenging. Given that stac interacts with Ca~V~1 CI module via the PCI element, we reasoned that other Ca~V~ and Na~V~ interacting proteins that engage a similar interface may suppress CaM-feedback. Intriguingly, recent atomic structures show that fhf interacts with Na~V~1 CI module via the PCI interface ([Figure 7A](#fig7){ref-type="fig"}) ([@bib107]). Yet, functionally, fhf isoforms are thought to modulate only voltage-dependent gating properties, with effects on Ca^2+^/CaM-regulation unknown ([@bib34]; [@bib63]; [@bib107]). To test whether fhf alters Na~V~ CDI, we undertook quantitative Ca^2+^ photo-uncaging of the skeletal muscle Na~V~1.4 isoform. We focused here on fhf1b given its modest baseline expression in skeletal muscle and pathological enrichment in critical illness myopathies ([@bib50]). [Figure 7B](#fig7){ref-type="fig"} reproduces baseline levels of CDI for Na~V~1.4 under control conditions. Co-expression of fhf1b abolished CDI ([Figure 7B--C](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), unveiling a novel role of fhf in tuning Ca^2+^-feedback of Na~V~ channels. To assess selectivity, we probed whether fhf alters CDI of Ca~V~1.3. In comparison to control conditions, fhf co-expression spared Ca~V~1.3 CDI ([Figure 7D--E](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) suggesting that fhf may be a selective modulator of Na~V~1.

![Fhf uses an allosteric mechanism to abrogate Ca^2+^-feedback of Na~V~1.4.\
(**A**) Structural comparison of Na~V~1.5 CI (green) in the presence of CaM alone (cyan, left) or both CaM (cyan) and fhf1b (purple). Fhf binding changes baseline conformation of CaM on Na~V~1 CI. (**B--C**) Co-expression of fhf1b abolishes CDI in Na~V~1.4 evoked via Ca^2+^ photo-uncaging. Format as in [Figure 1M--N](#fig1){ref-type="fig"}. Control data are reproduced from [Figure 1M--N](#fig1){ref-type="fig"} for comparison. (**D--E**) In sharp contrast, strong overexpression of fhf1b does not alter CDI of Ca~V~1.3~S~. Format as in [Figure 1A--B](#fig1){ref-type="fig"}. Control data reproduced from [Figure 1D](#fig1){ref-type="fig"} for comparison. (**F--G**) Fhf1 suppresses CDI of Na~V~1.4 tethered to CaM. Fusion of CaM protects Na~V~1.4 from competitive inhibitors such as CaM~1234~ (**G**). Format as in [Figure 1M--N](#fig1){ref-type="fig"}. (**H**) Structure of Ca~V~1.1 upstream CI elements (blue) composed of dual vestigial EF hands and preIQ segments isolated from cryo-EM structure of Ca~V~1.1 (PDBID, 5GJV). This domain is the primary interface for stac interaction in the Ca~V~1 CI. (**I**) Structural overlay of upstream CI elements of Ca~V~1.1 (PDBID, 5GJV) and Na~V~1.5 (PDBID, 4DCK) shows highly conserved dual vestigial EF hand segments while the fhf binding site is structurally divergent. (**J**) The divergence in the fhf binding interface in Ca~V~1.1 in comparison to Na~V~1.5 would introduce a steric clash that prohibits fhf binding to Ca~V~ channels.](elife-35222-fig7){#fig7}

Mechanistically, functional results along with atomic structures of Na~V~1 CI bound to CaM and fhf yield insights on mechanisms for CDI suppression ([@bib32]; [@bib107]; [@bib108]). Both fhf and CaM bind concurrently to Na~V~1 CI ([@bib107]; [@bib108]), with fhf binding triggering a conformational rearrangement of CaM ([Figure 7A](#fig7){ref-type="fig"}) ([@bib32]; [@bib107]). To experimentally validate allostery, we followed our strategy with Ca~V~1.3 and tethered CaM to Na~V~1.4 carboxy-tail. Reassuringly Na~V~1.4-CaM exhibits robust baseline CDI ([Figure 7F](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Whereas dominant negative CaM~1234~ typically abolishes CDI of Na~V~1.4 ([@bib8]), Na~V~1.4-CaM exhibits robust CDI despite CaM~1234~, confirming the protective nature of tethered CaM against competitive inhibitors ([Figure 7G](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). Co-expression of fhf1b, however, reduces CDI of Na~V~1.4-CaM ([Figure 7F--G](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Thus, like stac modulation of Ca~V~1, fhf overrides CaM signaling to Na~V~1.4 despite a tethered CaM, suggesting that fhf acts in allostery.

To garner a structural perspective, we turn to Na~V~1.5 CI/fhf complex ([Figure 7A](#fig7){ref-type="fig"}) as the atomistic basis of the stac/Ca~V~1 CI interaction is unknown ([@bib107]; [@bib108]; [@bib112]). Whereas the dual-vestigial EF hand segments of Na~V~1.5 and Ca~V~1.1 are similar ([Figure 7H--I](#fig7){ref-type="fig"}), the fhf binding interface of Na~V~1.5, including the preIQ loop diverges from corresponding segments of Ca~V~1.1 and introduces a steric clash ([Figure 7I--J](#fig7){ref-type="fig"}) ([@bib107]; [@bib113]). Thus, by leveraging structurally distinct loci on the CI module, fhf selectively diminish CaM signaling to Na~V~ channels. These findings point to a class of auxiliary proteins that selectively adjust Ca^2+^-dependent feedback to individual ion channel targets.

Engineering synthetic modulation of Ca~V~ channels {#s2-8}
--------------------------------------------------

As both stac and fhf tune Ca^2+^-feedback to individual Ca~V~ and Na~V~ targets by interacting with respective PCI segments, this mechanism furnishes a strategy to engineer synthetic channel modulators. We reasoned that introducing a short interaction motif into the PCI locus may permit inhibition of Ca~V~1 Ca^2+^-feedback by a novel protein. We chose the well-characterized RxxK motif from SLP-76 for its small size and high-affinity interaction with SH3 domain of Mona ([@bib37]) ([Figure 8A](#fig8){ref-type="fig"}). Co-expression of Mona SH3 with wildtype Ca~V~1.3~S~ demonstrated the persistence of CDI, confirming the suitability of these channels as a 'blank slate' to confer synthetic modulation ([Figure 8B--C](#fig8){ref-type="fig"}; [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). We replaced a 12-residue segment in the preIQ domain with the RxxK motif, as highlighted in [Figure 8A](#fig8){ref-type="fig"}, yielding Ca~V~1.3~RxxK~ engineered channels. As this locus is situated upstream of the IQ domain, this maneuver spares apoCaM prebinding. Under endogenous levels of CaM, Ca~V~1.3~RxxK~ exhibit robust baseline CDI ([Figure 8D--E](#fig8){ref-type="fig"}; [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). Co-expression of Mona SH3 with Ca~V~1.3~RxxK~ markedly diminished CDI ([Figure 8D--E](#fig8){ref-type="fig"}; [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}) , thus revealing engineered CDI suppression. These findings illustrate the versatility of the CI module as a regulatory hub and highlight the feasibility of developing synthetic modulators to tune Ca^2+^-feedback of ion channels.

![Engineering synthetic modulation of Ca~V~1 channels.\
(**A**) Left, schematic shows the atomic structure of Mona SH3 domain in complex with RxxK motif. Right, sequence alignment outlines strategy for insertion of RxxK motif into Ca~V~1.3, yielding Ca~V~1.3~RxxK~ to confer synthetic suppression of Ca~V~1.3 CDI by Mona SH3. (**B--C**) Ca~V~1.3~S~ expressed with and without Mona SH3 shows full CDI, confirming that wildtype Ca~V~1.3 CDI is insensitive to Mona SH3. Format as in [Figure 1A--B](#fig1){ref-type="fig"}. Control data are reproduced from [Figure 1D](#fig1){ref-type="fig"} for comparison. (**D--E**) Mona SH3 strongly diminishes CDI of Ca~V~1.3~RxxK~. Format as in [Figure 1A--B](#fig1){ref-type="fig"}. (**F**) Cartoon summarizes selective modulation of Ca^2+^/CaM signaling to Ca~V~1, and Na~V~1 channels with CaM, stac, and fhf.](elife-35222-fig8){#fig8}

Discussion {#s3}
==========

CaM is a dynamic regulator of Ca~V~1, Ca~V~2, and Na~V~1, affording millisecond-precision Ca^2+^-feedback of channel activity. Our findings suggest that distinct auxiliary regulatory proteins tune CaM signaling to individual targets selectively. Stac prevents CaM signaling to Ca~V~1, while fhf reduces signaling to Na~V~1 ([Figure 8F](#fig8){ref-type="fig"}). Parallel analysis of the two proteins delineates mechanisms and sets the stage for in-depth physiological analysis.

Relationship to prior studies of stac-Ca~V~ modulation {#s3-1}
------------------------------------------------------

Stac regulation of Ca~V~1 modifies multiple aspects of Ca~V~1 function. For Ca~V~1.1, stac3 enhances plasmalemmal trafficking ([@bib60]; [@bib74]; [@bib84]; [@bib112]; [@bib114]), and promotes conformational coupling to RyR ([@bib59]; [@bib85]). For Ca~V~1.2, however, stac1-3 isoforms slow inactivation ([@bib15]; [@bib84]; [@bib112]). Our work generalizes the latter effect to the Ca~V~1 family and further identifies a change in baseline channel openings (*P*~O~).

A few mechanistic nuances merit attention. First, stac binds to multiple Ca~V~1 segments including (1) the II-III linker ([@bib86]; [@bib112]), (2) the III-IV linker ([Figure 2D](#fig2){ref-type="fig"}), and (3) the carboxy-tail ([Figure 2D](#fig2){ref-type="fig"}) ([@bib15]; [@bib74]). Previous studies have shown that stac interaction with the II-III linker is important for Ca~V~1 trafficking in skeletal muscle ([@bib86]; [@bib112]). Chimeric analysis here suggests that stac interaction with the carboxy-tail is critical for tuning CDI. Prior analysis of Ca~V~1.2 triadic localization in myotubes suggested that the channel IQ domain may be important for stac binding ([@bib15]). However, FRET 2-hybrid assay indicates that stac interaction with the IQ is around tenfold weaker than with the PCI segment. Second, prior work also suggested that stac-mediated reduction in CDI results from competitive displacement of CaM by stac ([@bib15]). Functional experiments using Ca~V~1 tethered to CaM, however, suggest that stac does not compete with CaM. Consistent with this scheme, FRET 2-hybrid analysis shows that CaM binding with the CI module is intact even in the presence of stac. Third, key domains within stac relevant for Ca~V~ modulation remain controversial. Previous studies have identified the dual SH3 and C1 domains to be critical for stac effect on trafficking and coupling to RyR ([@bib16]; [@bib59]; [@bib60]; [@bib85]), while the C1 has been proposed to be critical for modifying Ca~V~1 CDI ([@bib15]; [@bib112]). Our findings instead suggest that the U-domain in the stac2 linker region is sufficient to fully recapitulate reduction in Ca~V~1 CDI. Notably, prior analysis of the C1 domain also included this linker ([@bib112]). Given these experimental findings, a simple possibility is that distinct subdomains within stac interact with disparate channel segments to support multifunctionality of stac. While the U-domain modifies channel inactivation, other subdomains may support plasmalemmal trafficking and conformational coupling.

Defining a general class of auxiliary modulators of CaM signaling {#s3-2}
-----------------------------------------------------------------

Although functionally divergent, Ca~V~1, Ca~V~2, and Na~V~1 feature a modular CI element with a common CaM interaction fingerprint and subsequently, shared mechanistic basis for Ca^2+^-regulation. For all three families, apoCaM prebinds the CI module while Ca^2+^/CaM interaction switches channels between discrete high and low *P*~O~ gating modes ([@bib9]). How do allosteric regulators override CaM-signaling? First, stac and fhf use unique interfaces on the channel CI to selectively tune Ca^2+^-feedback. Second, stac locks Ca~V~1 into a high *P*~O~ gating mode irrespective of whether apoCaM or Ca^2+^/CaM is bound, effectively disengaging the pore from CaM-conformational changes. For Na~V~1, despite fhf binding, CaM undergoes a profound Ca^2+^-dependent rearrangement ([@bib107]; [@bib108]) suggesting that fhf does not prevent Ca^2+^ binding to CaM or Ca^2+^/CaM interaction with effector interfaces. Instead, like stac and Ca~V~1, fhf may override CaM-dependent changes to Na~V~, akin to a clutch disengaging power transmission in mechanical systems. As fhf elicits a change in apoCaM conformation ([Figure 7A](#fig7){ref-type="fig"}) ([@bib32]; [@bib107]), baseline gating of Na~V~ may also be altered ([@bib34]; [@bib63]). This parallelism between stac and fhf hints at a shared mechanism.

Ca^2+^-binding proteins (CaBPs) ([@bib35]) also suppress CaM signaling to Ca~V~1 ([@bib53]; [@bib116]). Mechanistically, CaBPs exploit a mixed allosteric scheme -- at low concentrations, they engage distinct interfaces from CaM but at higher concentrations displace CaM ([@bib30]; [@bib77]; [@bib117]). The existence of other regulatory proteins that curtail Ca^2+^-feedback points to a general class of auxiliary regulators of CaM-signaling to targets beyond Na~V~1 and Ca~V~1. Identifying such molecular players is critical to understand how CaM signaling is orchestrated.

Biological implications of stac modulation of Ca~V~1 {#s3-3}
----------------------------------------------------

Stac1/2 isoforms are widely expressed in multiple brain regions, including both the hippocampus and the midbrain ([@bib72]; [@bib95]). Our experiments hint at low basal stac2 expression in guinea pig ventricular cardiac myocytes, although previous studies have failed to detect stac2 in murine heart ([@bib72]). Further quantitative analysis will help establish ambient stac levels including species-specific differences and potential modulatory effects on cardiac function. Interestingly, endogenous Ca~V~1 in both hippocampal and midbrain neurons ([@bib6]; [@bib75]) as well as ventricular cardiac myocytes exhibit CDI. As all stac variants shunted CDI of Ca~V~1 in HEK293, it is possible that stac function may be tightly regulated in native settings. One possibility is that stac abundance may be tuned developmentally ([@bib95]), pathologically, or via interacting proteins ([@bib88]). For instance, the transcription factor, NFAT binds to an upstream promoter region of stac2 gene to upregulate stac2 expression in osteoclasts as well as during hypoxic conditions in neural stem cells ([@bib45]; [@bib68]). Physiologically, as Ca~V~1 CDI is a potent homeostatic mechanism that prevents pathological Ca^2+^-overload ([@bib27]), a low concentration regime of stac may be advantageous. By modulating a subpopulation of Ca~V~1, stac may circumvent homeostatic requirements to amplify local Ca^2+^-signals via sustained Ca^2+^ influx. The C1 and SH3 domains may serve as scaffolds to localize stac to specific signaling complexes ([@bib16]; [@bib22]; [@bib23]). It is also possible that phosphorylation of stac may dynamically tune its function ([@bib43]). Resolving these complexities may unveil mechanisms that tune Ca~V~ function spatially and temporally.

In cardiac myocytes, CDI of Ca~V~1 is a key factor for action potential duration ([@bib57]; [@bib64]). Experimentally, this importance is inferred from prolongation of action potentials upon expression of mutant CaM~1234~ ([@bib4]). Yet, constitutive CaM expression may yield nonspecific effects ([@bib36]; [@bib104]) that obscure the net contribution of Ca~V~1 CDI ([@bib119]). Acute elevation of the U-domain bypasses these ambiguities and confirms a key role for Ca~V~1 CDI for cardiac action potentials. Pathophysiologically, differential expression of stac2 has been reported in right ventricular heart failure, hinting at a potential role in calcium remodeling during heart failure ([@bib25]).

Post-transcriptional modification of Ca~V~1.3 generates an assortment of variants with modified carboxy-termini ([@bib11]; [@bib42]). The apoCaM affinities of these variants are such that CaM fluctuations may redistribute channels between populations lacking or endowed with apoCaM ([@bib6]), evoking concomitant changes in maximal *P*~O~ and CDI of Ca~V~1.3 ([@bib3]). Stac uniformly locks these variants into a high *P*~O~ configuration incapable of CDI, thereby supporting reliable and persistent Ca^2+^-influx in spite of CaM. Notably, functional effects of Ca~V~1.3 alternative splicing have been shown to be cell-type specific suggesting that auxiliary regulators may tune channel properties ([@bib89]). Fitting with these regulatory possibilities, disruption of stac modulation of Ca~V~1.3 in Drosophila alters circadian rhythm ([@bib41]).

Biological implications of fhf modulation of Na~V~1 {#s3-4}
---------------------------------------------------

Unlike canonical fibroblast growth factors, fhf lack a secretory signal sequence ([@bib92]) and serve as intracellular proteins ([@bib90]). Four distinct fhf isoforms have been identified with tissue-specific expression in neurons, cardiomyocytes, and skeletal muscle ([@bib33]; [@bib50]; [@bib92]). Functionally, fhf isoforms promote Na~V~1 trafficking and fast inactivation ([@bib78]). More specifically, fhf adjust steady-state voltage-dependence of inactivation ([@bib63]), elicit a kinetically distinct long-term inactivation ([@bib26]), and modify resurgent current ([@bib115]). Our present findings suggest that fhf1 also tunes CDI of Na~V~1. Physiologically, Na~V~ CDI may be prominent during repetitive activity, as excess Ca^2+^ accumulation may inhibit Na currents. Thus, suppression of Na~V~1 CDI by fhf may enhance repetitive firing. Interestingly, loss of fhf1 and/or fhf4 result in diminished firing properties of cerebellar Purkinje neurons ([@bib12]; [@bib34]), while loss of fhf2 reduces cardiac conduction ([@bib79]; [@bib105]). It is possible that loss of fhf may enhance net CDI thus contributing to diminished excitability in these cells. As mutations in fhf1 are associated with epileptic encephalopathy ([@bib31]) and cardiac conduction disorders ([@bib38]) while mutations in fhf4 are linked to spinocerebellar ataxia ([@bib13]), resolving the dynamic interplay between CaM and fhf in tuning Na~V~1 may be critical for understanding pathogenic mechanisms.

New strategy for synthetic ion channel modulation {#s3-5}
-------------------------------------------------

Finally, our results highlight the possibility of engineering synthetic regulation to tune CaM signaling. While Ca~V~1.3 is insensitive to Mona SH3, insertion of an RxxK motif ([@bib37]) into the carboxy-tail preIQ segment allows latent modulation by Mona SH3. Given the structural similarity of the CI modules of Ca~V~1, Ca~V~2, and Na~V~1, and sequence variability within the preIQ domain, emerging protein engineering methods may be used to screen for synthetic modulators of related ion channel families. As the ligand specificity of SH3 domains can be custom-engineered ([@bib73]) and subcellular localization tuned via targeting motifs ([@bib49]), a custom library of synthetic regulators may be developed to combinatorially modify kinetic properties of Ca~V~1, Ca~V~2, or Na~V~1 channels with spatiotemporal specificity. Generalizing this approach may lead to the development of new tools to manipulate Ca^2+^ signaling.

In all, our findings unravel the elegant interplay between a novel class of allosteric regulators and CaM in orchestrating the activity of Ca~V~ and Na~V~ channels.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\               Designation                  Source or reference       Identifiers                                                     Additional information
  (species) or\                                                                                                                                      
  resource                                                                                                                                           
  --------------------------- ---------------------------- ------------------------- --------------------------------------------------------------- -----------------------------
  Gene (rat)                  β~2A~                        PMID: 1370480             GenBank: M80545                                                 

  Gene (rat)                  α~2~δ                        PMID: 8107966             NCBI: NM_012919                                                 

  Gene\                       Ca~V~1.2                     PMID: 1718988             NCBI: NM_001136522                                              
  (*Oryctolagus cuniculus*)                                                                                                                          

  Gene (rat)                  Ca~V~1.3~S~                  PMID: 20139964            GenBank: AF370009.1                                             

  Gene (rat)                  Ca~V~1.3~MQDY~               PMID: 24120865,\                                                                          
                                                           22284185                                                                                  

  Gene (human)                Ca~V~1.4~43\*~               PMID: 22069316                                                                            Laboratory of Dr.\
                                                                                                                                                     Soong Tuck Wah\
                                                                                                                                                     (National University\
                                                                                                                                                     of Singapore)

  Gene (human)                Ca~V~2.1 splice\             PMID: 12451115                                                                            
                              variant 37a(EFa)\                                                                                                      
                              with 43^+^/44^-^/47^-^                                                                                                 

  Gene (human)                Ca~V~2.2                     PMID: 1321501,\           GenBank: M94172.1                                               
                                                           10233069                                                                                  

  Gene (rat)                  Ca~V~2.3                     PMID: 8388125,\           NCBI: NM_019294.2                                               
                                                           18400181                                                                                  

  Gene (rat)                  Na~V~1.4                     PMID: 2175278                                                                             

  Gene (human)                stac1                        Origene                   NCBI: NP_003140.1                                               

  Gene (mouse)                stac2                        Origene                   NCBI: NP_666140.1                                               

  Gene (human)                stac3                        Origene                   NCBI: NP_659501.1                                               

  Gene (human)                fhf                          PMID: 8790420                                                                             Laboratory of Dr.\
                                                                                                                                                     Jeremy Nathans\
                                                                                                                                                     (Johns Hopkins\
                                                                                                                                                     University).

  Gene (human)                Mona SH3                     PMID: 12773374                                                                            Synthesized by\
                                                                                                                                                     Genscript based on\
                                                                                                                                                     sequence in publication

  Peptide\                    U-peptide                    this paper                                                                                Peptide sequence\
  (mouse)                                                                                                                                            KVDPVYETLRYGTSLALM\
                                                                                                                                                     NRSS synthesized\
                                                                                                                                                     by Genscript

  Competent cells\            DH5α                         Invitrogen:\                                                                              
  (*E. coli*)                                              18265017                                                                                  

  Cell line (human)           HEK293                       other                     RRID: [CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)     

  Biological sample\          aGPVM                        PMID: 24076394                                                                            Generated from\
  (guinea pig)                                                                                                                                       Hartley strain\
                                                                                                                                                     guinea pigs

  Antibody                    anti-stac1                   Abcam:\                                                                                   1:100
                                                           ab181157                                                                                  

  Antibody                    anti-stac2                   Abcam:\                                                                                   IHC -- 1:100\
                                                           ab156080                                                                                  WB -- 1:250

  Antibody                    anti-α-actinin               Sigma\                    RRID: [AB_476766](https://scicrunch.org/resolver/AB_476766)     1:300
                                                           Aldrich: A7811                                                                            

  Antibody                    goat anti- rabbit\           Abcam:\                   RRID: [AB_2650602](https://scicrunch.org/resolver/AB_2650602)   1:1000
                              IgG Alexa Fluor 594          ab150080                                                                                  

  Antibody                    goat anti-mouse IgG1\        Thermo\                   RRID: [AB_2535764](https://scicrunch.org/resolver/AB_2535764)   1:1000
                              Alexa Fluor 488              Fischer: A21121                                                                           

  Antibody                    Goat Anti-Rabbit\            Jackson\                  RRID: [AB_2307391](https://scicrunch.org/resolver/AB_2307391)   1:10,000
                              IgG (H + L)                  ImmunoResearch:\                                                                          
                                                           111-035-144                                                                               

  Recombinant DNA reagent     Ca~V~1.3~L~                  PMID: 20139964                                                                            Engineered from\
                                                                                                                                                     Ca~V~1.3~S~ and human\
                                                                                                                                                     long distal carboxyl\
                                                                                                                                                     tail (NCBI: NM_000718)

  Recombinant DNA reagent     Ca~V~2.3/1.3 CI              PMID: 24441587                                                                            

  Recombinant DNA reagent     Ca~V~1.3- CaM~WT~            PMID: 24441587                                                                            

  Recombinant DNA reagent     Ca~V~1.2- CaM~WT~            PMID: 15087548                                                                            

  Recombinant DNA reagent     Na~V~1.4-CaM                 this paper                                                                                Engineered by fusing\
                                                                                                                                                     CaM~WT~ carboxy-tail\
                                                                                                                                                     of Na~V~1.4

  Recombinant DNA reagent     Ca~V~1.3~RxxK~               this paper                                                                                Engineered from Ca~V~1.3~S~

  Recombinant DNA reagent     CFP-stac3                    this paper                                                                                stac3 was cloned\
                                                                                                                                                     into CFP vector\
                                                                                                                                                     with *NotI* and *XbaI*

  Recombinant DNA reagent     YFP-Ca~V~1.3 CI              PMID: 23591884                                                                            

  Recombinant DNA reagent     YFP-Ca~V~1.3 PCI             PMID: 23591884                                                                            

  Recombinant DNA reagent     YFP-Ca~V~1.3 IQ              PMID: 23591884                                                                            

  Recombinant DNA reagent     Ven-C1                       this paper                                                                                stac2 C1 was cloned\
                                                                                                                                                     into Venus vector\
                                                                                                                                                     (PMID: 26997269)\
                                                                                                                                                     with *NotI* and *XbaI*

  Recombinant DNA reagent     Ven-linker region            this paper                                                                                stac2 linker region\
                                                                                                                                                     was cloned into\
                                                                                                                                                     Venus vector\
                                                                                                                                                     (PMID: 26997269)\
                                                                                                                                                     with *NotI* and *XbaI*

  Recombinant DNA reagent     Ven-SH3-SH3                  this paper                                                                                stac2 SH3-SH3 was\
                                                                                                                                                     cloned into Venus\
                                                                                                                                                     vector (PMID:\
                                                                                                                                                     26997269) with\
                                                                                                                                                     *NotI* and *XbaI*

  Recombinant DNA reagent     Ven-U-motif                  this paper                                                                                stac2 U-motif was\
                                                                                                                                                     cloned into Venus\
                                                                                                                                                     vector (PMID:\
                                                                                                                                                     26997269) with\
                                                                                                                                                     *NotI* and *XbaI*

  Recombinant DNA reagent     stac2 (KVD/AAA)              this paper                                                                                Quickchange\
                                                                                                                                                     PCR with stac2

  Recombinant DNA reagent     stac2 (PVY/AAA)              this paper                                                                                Quickchange\
                                                                                                                                                     PCR with stac2

  Recombinant DNA reagent     stac2 (ETL/AAA)              this paper                                                                                Quickchange\
                                                                                                                                                     PCR with stac2

  Recombinant DNA reagent     stac2 (RYG/AAA)              this paper                                                                                Quickchange\
                                                                                                                                                     PCR with stac2

  Recombinant DNA reagent     stac2 (TSL/AAA)              this paper                                                                                Quickchange\
                                                                                                                                                     PCR with stac2

  Recombinant DNA reagent     stac2 (NRS/AAA)              this paper                                                                                Quickchange\
                                                                                                                                                     PCR with stac2

  Recombinant DNA reagent     stac2 (S/A)                  this paper                                                                                Quickchange\
                                                                                                                                                     PCR with stac2

  Sequence-based reagent      Ven-C1 forward\              this paper                                                                                cttctcgcggccgc\
                              primer                                                                                                                 tatgaccgaa atga\
                                                                                                                                                     gcgagaa

  Sequence-based reagent      Ven-C1 reverse\              this paper                                                                                tcagaattctagattat\
                              primer                                                                                                                 tgctggt gggagatctc

  Sequence-based reagent      Ven-linker region\           this paper                                                                                cttctcgcggccgcta\
                              forward primer                                                                                                         catctttt cgacgcaact

  Sequence-based reagent      Ven-linker region reverse\   this paper                                                                                tcagaattctagatta\
                              primer                                                                                                                 gtacatg ggccccacg

  Sequence-based reagent      Ven-SH3-SH3 forward\         this paper                                                                                cttctcgcggccgc\
                              primer                                                                                                                 ttcctacgt cgccctct

  Sequence-based reagent      Ven-SH3-SH3 reverse\         this paper                                                                                tcagaattctagattat\
                              primer                                                                                                                 cagatctct gccaaggag

  Sequence-based reagent      Ven-U-motif forward\         this paper                                                                                cttctcgcggccgctaagg\
                              primer                                                                                                                 tggac ccagtttatga

  Sequence-based reagent      Ven-U-motif reverse\         this paper                                                                                tcagaattctagattag\
                              primer                                                                                                                 ctggaa cggttcatcag

  Sequence-based reagent      stac2 (KVD/AAA) sense        this paper                                                                                ctactgggaccagcgg\
                                                                                                                                                     ggcggcgg ccccagt\
                                                                                                                                                     ttatgagacgc

  Sequence-based reagent      stac2 (KVD/AAA) antisense    this paper                                                                                gcgtctcataaactggg\
                                                                                                                                                     gccgccgc cccgctgg\
                                                                                                                                                     tcccagtag

  Sequence-based reagent      stac2 (PVY/AAA) sense        this paper                                                                                ccagcgggaaggtggac\
                                                                                                                                                     gcagc tgctgagacgct\
                                                                                                                                                     gcgctatg

  Sequence-based reagent      stac2 (PVY/AAA) antisense    this paper                                                                                catagcgcagcgtctc\
                                                                                                                                                     agcagct gcgtccacc\
                                                                                                                                                     ttcccgctgg

  Sequence-based reagent      stac2 (ETL/AAA) sense        this paper                                                                                ggtggacccagttt\
                                                                                                                                                     atgcggcgg cgcgct\
                                                                                                                                                     atggcacctcc

  Sequence-based reagent      stac2 (ETL/AAA) antisense    this paper                                                                                ggaggtgccatagcgc\
                                                                                                                                                     gccgcc gcataaact\
                                                                                                                                                     gggtccacc

  Sequence-based reagent      stac2 (RYG/AAA) sense        this paper                                                                                cccagtttatgagacgc\
                                                                                                                                                     tggccgc tgccacctcc\
                                                                                                                                                     ctggcactgatg

  Sequence-based reagent      stac2 (RYG/AAA) antisense    this paper                                                                                catcagtgccaggg\
                                                                                                                                                     aggtggca gcggccagc\
                                                                                                                                                     gtctcataaactggg

  Sequence-based reagent      stac2 (TSL/AAA) sense        this paper                                                                                acgctgcgctatgg\
                                                                                                                                                     cgccgccgc ggcactga\
                                                                                                                                                     tgaaccg

  Sequence-based reagent      stac2 (TSL/AAA) antisense    this paper                                                                                cggttcatcagtgc\
                                                                                                                                                     cgcggcggc gccatag\
                                                                                                                                                     cgcagcgt

  Sequence-based reagent      stac2 (NRS/AAA) sense        this paper                                                                                gatgtgctgctga\
                                                                                                                                                     agctggcagcg gccatc\
                                                                                                                                                     agtgccagggaggtg

  Sequence-based reagent      stac2 (NRS/AAA) antisense    this paper                                                                                cacctccctggc\
                                                                                                                                                     actgatggccgc tgcc\
                                                                                                                                                     agcttcagcagcacatc

  Sequence-based reagent      stac2 (S/A) sense            this paper                                                                                cactgatgaacc\
                                                                                                                                                     gttccgccttc agcag\
                                                                                                                                                     cacatctg

  Sequence-based reagent      stac2 (S/A) antisense        this paper                                                                                cagatgtgctgctga\
                                                                                                                                                     aggcgg aacggttca\
                                                                                                                                                     tcagtg

  Software, algorithm         PyMOL                        <http://www.pymol.org/>   RRID: [SCR_000305](https://scicrunch.org/resolver/SCR_000305)   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Molecular biology and peptide synthesis {#s4-1}
---------------------------------------

Ca~V~1.2, Ca~V~1.3, Ca~V~1.4~43\*~, Ca~V~2.1, Ca~V~2.2, Ca~V~2.3, and Na~V~1.4 variants were unmodified from previously published constructs: Ca~V~1.2 (NM001136522) ([@bib109]), Ca~V~1.2-CaM~WT~ ([@bib69]), Ca~V~1.3~S~ (AF370009.1), Ca~V~1.3~L~ engineered from Ca~V~1.3~S~ and human long distal carboxyl tail (NM000718) ([@bib62]), RNA-edited variant Ca~V~1.3~MQDY~ ([@bib6]; [@bib42]), Ca~V~1.4~43\*~ was gifted from Dr. Soong Tuck Wah (National University of Singapore), Ca~V~2.1 splice variant 37a(EFa) with 43^+^/44^-^/47^−^ ([@bib93]) was gifted from Dr. Terry Snutch (University of British Columbia), Ca~V~2.2 ([@bib47]), Ca~V~2.3 ([@bib70]), Na~V~1.4 ([@bib101]). Stac variants were purchased from Origene: human stac1 mRNA transcript 1 (NP003140.1), mouse stac2 (NP666140.1), and human stac3 isoform 2 (NP659501.1). U-peptide was synthesized by Genscript (KVDPVYETLRYGTSLALMNRSS). Fhf variants were gifted from Dr. Gordon Tomaselli and Dr. Jeremy Nathans (Johns Hopkins University).

Cell culture and transfection of HEK293 cells {#s4-2}
---------------------------------------------

For whole-cell electrophysiology, single-channel electrophysiology, and immunohistochemistry, HEK293 cells (ATCC; mycoplasma tested negative) were cultured on glass coverslips in 10 cm dishes and transfected by a calcium phosphate method ([@bib82]) with the following amounts of DNA: 3 µg of SV40 T antigen to enhance expression, 2--8 µg of α~1~-subunit of Ca^2+^ or Na^+^ channel depending on expression, 8 µg from rat β~2A~ ([@bib80]) (M80545), 8 µg from rat α~2~δ ([@bib100]) (NM012919.2), and 8 µg of the stac1, stac2, or stac3 variants indicated.

For FRET two-hybrid experiments, cells were cultured on glass-bottom dishes and transfected with a standard polyethylenimine protocol ([@bib51]). Epifluorescence measurements were recorded 1--2 days after transfection.

Adult guinea pig ventricular myocyte isolation {#s4-3}
----------------------------------------------

Adult guinea pig ventricular myocytes (aGPVMs) were isolated from whole hearts of Hartley strain guinea pigs 3--4 weeks old (250--350 g). Guinea pigs were anesthetized via intraperitoneal injection with pentobarbital (35 mg/kg). Hearts were then excised, and single ventricular myocytes were isolated following a previously published protocol ([@bib48]). Cells were plated on glass coverslips that were laminin (20 µg/mL) coated overnight at 4°C.

Immunohistochemistry aGPVMs plated on glass coverslips were first washed three times with cold PBS and then fixed in 3.7% paraformaldehyde (15710, Electron Microscopy Sciences) in PBS for 15 min. After washing three times with PBS, cells were permeabilized in cold 0.5% Triton X-100 in tris buffered saline (TBS) for 20 min and then blocked with 10% goat serum in PBS for 1 hr at room temperature. Cells were incubated overnight at 4°C in primary antibodies diluted in antibody diluent solution (IW-1000, IHC World): monoclonal anti-α-actinin (sarcomeric) antibody produced in mouse (1:300, A7811), anti-STAC (stac1) antibody \[EPR12805\]-N-terminal (1:100, ab181157) or anti-STAC2 (stac2) antibody-N-terminal (1:100, ab156080) produced in rabbit. Next day, cells were rinsed three times with 0.05% TWEEN20 (Sigma P9416) in TBS (TBS-T) for 5 min each. In the dark, cells were incubated with secondary antibodies (1:1000): goat anti-mouse IgG1 Alexa Fluor 488 (1:1000, A21121), goat anti-rabbit IgG Alexa Fluor 594 (1:1000), and DAPI (1:10000) diluted in antibody solution for 45 min at room temperature and then washed three times with TBS-T for 5 min each. Stained cells were mounted with prolong gold mounting media (Invitrogen) on a microscope slide (Fischer Scientific).

Transfected HEK293 were immunostained following a similar protocol to that of aGPVM, but were not labelled with sarcomeric primary antibody and its respective secondary antibody.

Western blot aGPVMs and HEK293 cells were washed twice with PBS buffer. Cells were harvested with 1 mL 1x RIPA buffer (20--188, Sigma Aldrich) containing half a tablet of complete mini-EDTA-free protease inhibitor (11836170001, Sigma Aldrich) and incubated at 4°C for 30 min. Samples were centrifuged at 15,000 RPM for 15 min, and the pellet was discarded. Then, 2--5 µg of proteins in the supernatant were heated at 37°C for 30 min with 2x Laemmli sample buffer (S3401, Sigma Aldrich). Samples were loaded into 4--12% gradient gel (NP0335BOX, Invitrogen) with PageRuler plus prestained protein ladder (26619, Invitrogen) and run at 100 V for 2 hr at room temperature in running buffer: 1x NuPAGE MOPS SDS running buffer: 50 mM MOPS, 50 mM Tris base, 0.1% SDS, 1 mM EDTA, pH to 7.7. Proteins were transferred on ice from the gel to nitrocellulose membrane (10600003, GE Healthcare Life science) for 75 min at 10 V in transfer buffer: 24 mM Tris base, 192 mM glycine, 20% v/v methanol. Membrane was blocked with 5% (w/v) Blotting-Grade-Blocker (1706404, Bio-Rad) in 1x TRIS-buffered saline for 1 hr at 4°C. Primary antibody for stac2 (1:250) was added to the blocking buffer with 0.1% (v/v) Tween 20 (1706404, Bio-Rad) and incubated overnight at 4°C. Next day, the membrane was washed three times for 5 min each with TBS with 0.1% (v/v) Tween 20 (TBS-T). The secondary antibody (111-035-144, Jackson ImmunoResearch; 1:10,000) was added to the blocking buffer with 0.1% (v/v) Tween 20 and incubated for 1 hr. The membrane was washed again three times for 5 min each with TBS-T. Finally, western blots were developed with SuperSignal West Pico Chemiluminescent Substrate (34580, ThermoFischer) and images were collected on an Alpha InnoTech FluorChem HD2 imaging system.

Confocal optical imaging {#s4-4}
------------------------

Images of immunostained tissue slices and cells were captured with either an Olympus Fluorview FV300 confocal laser scanning microscope or an LSM780 (Carl Zeiss, Oberkochen, Germany) confocal microscope. For the FV300, we used Fluoview software (Olympus) with a PlanApo 403 or 603 oil objective (NA 1.40, PLAPO60XO3; Olympus). Argon laser (488 nm) was used to excite Alexa Fluor 488 (green), and Helium Neon (HeNe) Green Laser was used to excite Alexa Fluor 594 (red). Olympus optical filters used were 442/515 nm excitation splitter (FV-FCV), 570 nm emission splitter (FV-570CH), BA510 IF and BA530RIF for green emission channel, and 605 BP ﬁlter for red channel. Images were processed in ImageJ. Similar settings were used for the LSM780 setup.

Whole-cell electrophysiology {#s4-5}
----------------------------

Whole-cell voltage-clamp recordings for HEK293 were collected at room temperature 1--2 days after transfection with Axopatch 200A (Axon Instruments). Glass pipettes (BF150-86-10, Sutter Instruments) were pulled with a horizontal puller (P-97; Sutter Instruments Company) and fire polished (Microforge, Narishige, Tokyo, Japan) to have 1--3 MΩ resistance. Recordings were low-pass filtered at 2 kHz and sampled at 10 kHz with P/8 leak subtraction and 70% series resistance and capacitance compensation. For recordings of Ca~V~1.2 ([Figure 1A--B](#fig1){ref-type="fig"}, [Figure 5I--K](#fig5){ref-type="fig"}, [Figure 6B](#fig6){ref-type="fig"}), Ca~V~1.3~S~ ([Figure 1C--D](#fig1){ref-type="fig"}, [Figure 3---figure supplement 1A--B and and G](#fig3s1){ref-type="fig"}, [Figure 7D--E](#fig7){ref-type="fig"}, and [Figure 8B--C](#fig8){ref-type="fig"}), Ca~V~1.4~43\*~ ([Figure 1E--F](#fig1){ref-type="fig"}), Ca~V~2.2 ([Figure 1I--J](#fig1){ref-type="fig"}), Ca~V~2.3/1.3 CI chimera ([Figure 2E--F](#fig2){ref-type="fig"}), Ca~V~1.3-CaM ([Figure 3A--B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C--F](#fig3s1){ref-type="fig"}, and [Figure 5G--H](#fig5){ref-type="fig"}), Ca~V~1.2-CaM ([Figure 2C--D](#fig2){ref-type="fig"}, [Figure 5A--F](#fig5){ref-type="fig"}) and Ca~V~1.3~RxxK~ ([Figure 8D--E](#fig8){ref-type="fig"}) exogenously expressed in HEK293 cells, the internal solution contained (in mM): CsMeSO~3~, 114; CsCl~2~, 5; MgCl~2~, 1; MgATP, 4; HEPES, 10; BAPTA, 10; adjusted to 295 mOsm with CsMeSO~3~ and pH 7.4 with CsOH. The external solution contained (in mM): TEA-MeSO~3~, 140; HEPES, 10; CaCl~2~, or BaCl~2~ 40; adjusted to 300 mOsm with TEA-MeSO~3~ and pH 7.4 with TEA-OH. For recordings of Ca~V~2.1 ([Figure 1G--H](#fig1){ref-type="fig"}) and Ca~V~2.3 ([Figure 1K--L](#fig1){ref-type="fig"}), the internal solution contained (in mM): CsMeSO~3~, 135; CsCl~2~, 5; MgCl~2~, 1; MgATP, 4; HEPES, 10; EGTA, 1; adjusted to 295 mOsm with CsMeSO~3~ and pH 7.4 with CsOH. The external solution contained (in mM): TEA-MeSO~3~, 140; HEPES, 10; CaCl~2~, or BaCl~2~ 5; adjusted to 300 mOsm with TEA-MeSO~3~ and pH 7.4 with TEA-OH. At a holding potential of −80 mV, we used a family of test pulses from −30 mV to +50 mV with repetition intervals of 20 s. Custom MATLAB (Mathworks) software (<https://github.com/manubenjohny/WCDTY>; copy archived at <https://github.com/elifesciences-publications/WCDTY>) was used to determine peak current and fraction of peak current remaining after either 300 ms (*r*~300~) or 800 ms (*r*~800~) of depolarization.

We incubated aGPVMs for 20--48 hr after isolation in 5 µM ryanodine for 5--10 min before we collected whole-cell recordings. The internal recording solution contained (in mM) CsMeSO~3~, 114; CsCl~2~, 5; MgCl~2~, 1; MgATP, 4; HEPES, 10; BAPTA, 10; ryanodine, 0.005 adjusted to 295 mOsm with CsMeSO~3~ and pH 7.4 with CsOH. Cells were sealed in Tyrodes solution, which contained (in mM): NaCl, 135; KCl, 5.4; CaCl~2~, 1.8; MgCl~2~, 0.33; NaH~2~PO~4~, 0.33; HEPES, 5; glucose, 5 (pH 7.4). For CDI measurements, external solutions containing (in mM): TEA-MeSO~3~, 140; HEPES, 10; CaCl~2~, or BaCl~2~ 40; adjusted to 300 mOsm with TEA-MeSO~3~ and pH 7.4 with TEA-OH were perfused. Welch's T-test was used to verify statistical significance among the population data.

For CDI recordings, we determined required sample size based on power analysis. Based on historical estimates of normal variation in CDI/CDF measurements, we computed the sample size required such that type I and type II errors are 5% to be 3.5. Thus, we obtained at least four independent measurements for all electrophysiological experiments.

Current-clamp recordings of aGPVMs were performed on the same setup and were filtered at 5 kHz and sampled at 25 kHz. The internal solution contained (in mM): K glutamate, 130; KCl, 9; NaCl, 10; MgCl~2~, 0.5; EGTA, 0.5, MgATP, 4; HEPES, 10; adjusted to pH 7.3 with KOH. The external solution contained (in mM): NaCl, 135; KCl, 5.4; CaCl~2~, 1.8; MgCl~2~, 0.33; NaH~2~PO~4~, 0.33; HEPES, 5; glucose, 5 (pH 7.4). The time from upstroke to 80% repolarization (*APD*~80~) was measured with MATLAB (Mathworks) and used as a metric for comparing physiological output between peptide treated and untreated. For experiments with U-peptide, peptide was dissolved in ddH~2~O to 2 mg/mL and then diluted to 500 μM in the appropriate internal solution.

Single-channel electrophysiology {#s4-6}
--------------------------------

Single-channel recordings were performed at room temperature using an on-cell configuration previously established in the laboratory ([@bib98]) with the same setup as used for whole-cell electrophysiology. Glass pipettes were pulled and polished from ultra-thick-walled borosilicate glass (BF200-116-10, Sutter Instruments) and coated with sylgard to have 5--10 MΩ resistance. Recordings were filtered at 2--5 kHz. The pipette solution contained (in mM): TEA-MeSO~3~, 140; HEPES, 10; BaCl~2~ 40; adjusted to 300 mOsm with TEA-MeSO~3~ and pH 7.4 with TEA-OH. The external solution contained (in mM): K glutamate, 132; KCl, 5; NaCl, 5; MgCl~2~, 3; EGTA, 2; HEPES, 10; adjusted to 300 mOsm with glucose and pH 7.4 with KOH. Cell-attached single-channel currents were measured during 200 ms voltage ramps between −80 and +70 mV (portions between −50 and 40 mV displayed and analyzed) as previously described. For each patch, we recorded 80--150 sweeps with a repetition interval of 12 s. Patches were analyzed as follows: (1) The leak for each sweep was fit and subtracted from each trace. (2) The unitary current relation, *i*(*V*), was fit to the open-channel current level using the following equation:

$i\left( V \right) = - g \cdot \left( V - V_{\text{S}} \right) \cdot \exp\left( - \left( V - V_{\text{S}} \right) \cdot z \cdot F/\left( R \cdot T \right) \right)/\left( 1 - \exp\left( - \left( V - V_{\text{S}} \right) \cdot z \cdot F/\left( R \cdot T \right) \right) \right)$ where *g* is the single-channel conductance (\~0.2 pA/mV), *z* is the apparent valence of permeation (\~2.1), *F* is Faraday's constant, *R* is the gas constant, and *T* is the temperature in degrees Kelvin (assumed room temperature). These parameters were held constant for all patches, except for slight variations in the voltage-shift parameter *V*~s~ \~ 35 mV, as detailed below. (3) All leak-subtracted traces for each patch were averaged (and divided by the number of channels in the patch) to yield an *I--V* relation for that patch. As slight variability in *V*~S~ was observed among patches, we calculated an average *V*~S~ for each construct, *V*~S,AVE~. The data from each patch were then shifted slightly in voltage by an amount Δ*V* = *V*~S,AVE~ -- *V*~S~, with Δ*V* typically about ±5 mV. This maneuver allowed all patches for a given construct to share a common open-channel GHK relation. Thus shifted, the *I--V* relations obtained from different patches for each condition/construct were then averaged together. (4) *P*~O~ at each voltage was determined by dividing the average *I* (determined in step three above) into the open-channel GHK relation. Channel number was determined by the maximal number of overlapping opening events upon application of the channel agonist Bay K8644 (5 μM) at the end of each recording. For modal analysis, a dashed line discriminator was chosen to be the average single-trial *P*~O~ = 0.075 such that traces with average single-trial *P*~O~ \>0.075 were categorized as high *P*~O~ while the remaining traces were considered to be low *P*~O~.

Quantitative calcium photo-uncaging {#s4-7}
-----------------------------------

All Ca^2+^-uncaging experiments were conducted on a Nikon TE2000 inverted microscope with a Plan Fluor Apo 40 × oil objective as previously described ([@bib8]). Briefly, a classic Cairn UV flash photolysis system was used for Ca^2+^-uncaging with brief UV pulses of \~1.5 ms in duration powered by a capacitor bank of up to 4000 μF charged to 200--290V. For concurrent Ca^2+^ imaging, Fluo4FF and Alexa568 dyes were dialyzed via patch pipette and imaged using Argon laser excitation (514 nm). Background fluorescence for each cell was measured prior to pipette dialysis of dyes and subtracted subsequently. A field-stop aperture was used to isolate fluorescence from individual cells. Dual-color fluorescence emission was attained using a 545DCLP dichroic mirror, paired with a 545/40 BP filter for detecting Fluo4FF, and a 580LP filter for detecting Alexa568. Typically, uncaging experiments were conducted after \~2 min of dialysis of internal solution. Welch's T-test was used to verify statistical significance between the population data.

For all Ca^2+^-uncaging experiments, the internal solution contained (in mM): CsMeSO~3~, 120; CsCl, 5; HEPES (pH 7.4 with CsOH), 10; Fluo-4FF pentapotassium salt (Invitrogen), 0.01; Alexa 568 succinimidyl ester (Invitrogen), 0.0025; Citrate, 1; DM-Nitrophen EDTA (DMN) and CaCl~2~ were adjusted to obtain the desired Ca^2+^ flash. Typically, for flashes in the range 0.5--2 μM, DMN, 1 mM; and CaCl~2~, 0.7 mM. For the 2--8 μM range, DMN, 2 mM; and CaCl~2~, 1.4 mM. For larger Ca^2+^ steps, DMN, 4 mM; and CaCl~2~, 3.2 mM. As DMN can bind Mg^2+^, all experiments were conducted with 0 mM Mg^2+^ internally. For all Na channel experiments, the bath solution contained (in mM): TEA-MeSO~3~, 45; HEPES (pH 7.4), 10; NaCl, 100; at 300 mOsm, adjusted with TEA-MeSO~3~.

FRET-two-hybrid assay {#s4-8}
---------------------

To collect a range of donor molecule (*D*~free~) concentrations, HEK293 cells were transfected with combinations of DNA ratios. Cells were immersed in 2 mM Ca^2+^ Tyrodes solution, which contained (in mM): NaCl, 138; KCl, 4; CaCl~2~, 2; MgCl~2~, 1; HEPES, 10; glucose, 10. Three-cube FRET fluorescence measurements were performed under resting Ca^2+^ concentrations on an inverted fluorescence microscope. FRET efficiency (*E*~A~ and *E*~D~) was calculated for each cell ([@bib29]) and a binding curve, either *E*~A~ = \[*D*~free~\]/(*K*~d,EFF~ + \[*D*~free~\]) · *E*~A,max~ or *E*~D~ = \[*A*~free~\]/(*K*~d,EFF~ + \[*A*~free~\]), was fit to compute the effective dissociation constant (*K*~d,EFF~).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Allosteric regulators selectively shunt Ca^2+^-feedback of Ca~V~ and Na~V~ channels\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Bruce P Bean (Reviewer \#2); Dejian Ren (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study describes two classes of proteins, stac and fhf, interfere with CaM binding to voltage-dependent Ca and Na channels, both of which have a CaM binding domain that stacs and fhfs can also bind, thereby reducing Ca-dependent inactivation. The data offer a potential explanation for why CaM can have targeted effects, and reveal interactions among channel modulators that have posed long-standing puzzles, e.g. why CaM sometimes has effects on channels with CaM binding domains but sometimes not.

Essential revisions:

1\) The primary results on how stac modulates Ca channels are all with overexpression. Consequently, it is unclear to what extent normal expression levels participate in regulation of currents and what the nature of the competition (or not) with CaM is. Additional approaches to clarify these points are suggested by the reviewers.

2\) The immunostaining in Figure 1 of stac expression in cardiac neurons is not convincing. The reviewers suggest either removal of these data or a more extensive validation of the antibodies and/or other means of verifying the signal.

3\) A number of discrepancies with the published literature were noted. These should be acknowledged and discussed, and where possible, resolutions proposed.

4\) The caliber of the data is high but the highly dramatic, hyperbolic language detracts from the overall quality of the manuscript. While some stylistic freedom is appropriate, it must not interfere with accuracy and readability. A few specific sentences are noted in the reviews, but the full manuscript should be revised substantially with this idea in mind.

The basis for these comments, in the reviewers\' words, is included below, under \"Major Comments\" to facilitate the revision.

Title: It is not clear that the prevention of CaM modulation of channels by stac is meaningfully described by the word \"shunt.\" Possibly a more straightforward work like \"prevent\" or \"interferes with\" would be more appropriate.

Major comments (in the reviewers\' words; explaining basis for the essential revisions requested):

1\) Interpretations from overexpression. A general issue concerning the significance is that the key results in how stac proteins modify behavior of calcium channels are all with overexpression of stac, and there is no evidence that there is any \"tuning\" from this mechanism physiologically (in stark contrast to previous data with stac3 in skeletal muscle, where the physiological relevance is quite clear). Previous studies in both heart and neurons show prominent calcium-dependent inactivation, giving little reason to think that stac inhibition of this effect is important. The author\'s experiments here disrupting the interaction also suggest little or no physiological significance in cardiac muscle. An RNAi or knock-out approach would be better suited for testing physiological relevance for native Ca~v~1.2 or Ca~v~1.3 channels.

Also, the authors conclude that STAC doesn\'t compete with CaM to suppress CDI, a mechanism apparently contrast to the \"competition-based\" mechanism implicated by Campiglio et al., 2018. While the multiple experiments in this manuscript do suggest that the authors\' model is more convincing, a major evidence the authors used to \"explicitly rule out\" that a displacement of CaM binding by STAC is necessary for CDI suppression is by fusing CaM to Ca~V~\'s C-terminus to increase local CaM concentration (Figure 3F-I). However, such a fusion still can\'t rule out that overexpressing STAC (as done in the paper) displaces CaM\'s binding to the site. One way to solve this problem is perhaps by directly monitor CaM binding with and without STAC. An easier, though less direct, experiment is perhaps to overexpress CaM (as done in the single channel recordings in Figure 4) and to test whether STAC still eliminates CDI when CaM binding is presumably saturated.

2\) Immunostaining. A potentially novel result is the immuno evidence for stac2 in cardiac muscle. Previous work concluded stac3 is expressed in skeletal muscle and stac1 and stac2 in neurons, with no clear expression of any in cardiac muscle. But here the staining for stac2 is weak and there is no validation of the antibody, so this is very weak evidence -especially since the disruption experiment suggests no basal modulation that might suggest endogenous stac expression. Everyone who has worked with antibodies knows how easy it is to get weak off-target staining. The title of Figure 1 \"Stac2 is differentially expressed in cardiac myocytes and neurons\" is also somewhat misleading, as the experiments don\'t examine stac2\'s expression in neurons and the immunostaining data is not quantitative.

3\) Relation to other work. The authors report several interesting findings in this paper. First, they found that all the STACs (STAC1-3) can abolish/reduce the calmodulin (CaM)-mediated CDI of L-type (Ca~V~1 sub-family) Ca~V~s (a finding also recently reported by other groups, e.g. Polster et al., 2015, Campiglio et al., 2018). Second, the authors used the FRET protein-interaction assay and found that STAC3 interacts with the proximal Ca^2+^-inactivating (PCI) segment of the Ca^2+^-inactivating (CI) module in the C-terminus of Ca~V~1.3, but not with the other segments, including the IQ motif immediately C-terminal to the PCI and the II/III loop previously found by others to interact with STACs in the Ca~V~1.1 (Yuen et al., 2017, Polster et al., 2018) or Ca~V~1.2 (Campiglio et al., 2018). Intriguingly, the authors found that a short \"linker\" between the C1 and the SH3 regions on STAC is required for STAC\'s suppression of CDI, and infusion of a U-motif peptide derived from this linker region is sufficient to remove CDI. This finding again is apparently contrast with a previous conclusion by others that the C1 domain is the major CDI-slowing determinant.

Mechanistically, the authors conclude that STACs allosterically control CDI and \"lock\" the channel into a high opening probability state, a mechanism contrast to a previously proposed one by which STAC competes with CaM. Interestingly, the authors also discovered that the regulation of Na~V~\'s CDI by FGF has a structural requirement analogous to that of the regulation of Ca~V~s by STACs. Perhaps the most remarkable finding in the paper is that the authors were able to introduce an artificial Mona SH3-binding sequence in the PCI region to confer complete CDI inhibition by Mona SH3, a protein that doesn\'t affect the wild-type Ca~V~. Overall, there are many apparent \"discrepancies\" between the current paper and the two PNAS papers (Yuen et al., 2017, Campiglio et al., 2018), ranging from the STAC binding sites on Ca~V~s (PCI in this paper vs. the IQ motif and II/III loop in the others), and the important segment on STAC (linker vs. C1) to the mechanism (allosteric vs. competitive). The authors might want to elaborate the differences and provide potential explanations.

4\) Writing. A comment on style: The authors use a prose style with so many dramatic statements and intensifying adjectives that it will likely irritate and even alienate some readers. In my opinion, a more sober presentation in a standard style that lets the results speak for themselves is more effective. Insisting on telling the reader how important the results are (like repeatedly using \"Remarkably\" for results that seem very straightforward, like seeing similar effects on Ca~v~1.4 as for Ca~v~1.1, Ca~v~1.2, and Ca~v~1.3) can make the reader think that he or she is receiving a sales pitch rather than being told results. There are too many examples of over-dramatic language to list but one was the statement that stac and fhf exert \"orthogonal\" control because one interacts with calcium channels and one with sodium channels. Calmodulin interacts with dozens if not hundreds of proteins, and of course there are ways that the interactions are regulated differently -- is each one of these an orthogonal dimension? I had a similar reaction to sentences like \"Synergistic analysis of the two proteins delineate mechanisms that confer personalized modulation and inform upon physiological consequences\" and \"Repurposing this modulatory principle furnishes a general strategy for engineering synthetic modulators that patently switch CaV and NaV channel feedback.\" (These sentences lie between a lack of clear meaning and inaccuracy.)

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Allosteric regulators selectively prevent Ca^2+^-feedback of Ca~V~ and Na~V~ channels\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Richard Aldrich (Senior Editor), a Reviewing Editor, and two reviewers.

The manuscript has been improved but there are some important issues that need to be addressed, as outlined below:

One reviewer (whose comments are included verbatim below) identified some inconsistencies in the match between figure panels cited in the text and in the figures, and also noted that the control plots in the last two supplementary figures (Figure 7---figure supplement 1 and Figure 8---figure supplement 1) appear to be identical, but the duplication (if these are indeed duplicates) is neither justified nor indicated in the legends. The same panel appears to be duplicated in Figure 1---figure supplement 1 and Figure 3---figure supplement 1, although in the latter it is labeled as N=6 instead of N=9 as in the other three panels. These issues raise concern about the care with which the manuscript was assembled and presented.

Before a final decision is rendered, please ensure (1) that the correct data and figure panels are present throughout the manuscript, (2) that they are called correctly, (3) that any duplication of panels to facilitate comparison is clearly indicated as such (with appropriate justification for a common control group), and (4) that there are no other related errors. In your revision, please clearly indicate the corrections that have been made.

Reviewer comments:

The revision generally addresses the main issues raised on the original version. The data are extensive and comprise a very comprehensive picture of the molecular interactions with the multiple STAC proteins with multiple calcium channels. It is still unproven that the STAC interaction functions physiologically to \"tune\" Ca-dependent channel inactivation, but the authors make a good point that testing this via RNAi would be technically challenging given current experimental systems and making knock-out mice would be a major project. The fact that STAC proteins are heavily expressed in the brain gives some credence to the idea that they could be functionally important in neurons, or knock-outs.

The authors need to proof-read the manuscript more carefully. The reviewer copy was hard to read, as it consisted of a pdf incorporating cross-outs and additions, which made spotting errors difficult. However, it is obvious that not all changes in re-numbering figure references were done correctly (e.g. in the first paragraph of the subsection "Stac selectively suppresses Ca^2+^-feedback of Ca~V~1 channels", Figure 2A should now be 1A, and in the second paragraph of the subsection "Stac interacts with CaV1 CI module to elicit CDI suppression", Figure 3B should be 2B).

Also the fact that the figures were not numbered made the reviewing process more difficult than was necessary. Also, at the end of the manuscript there are supplementary figures that are exact duplicates.

10.7554/eLife.35222.025

Author response

> Essential revisions:
>
> 1\) The primary results on how stac modulates Ca channels are all with overexpression. Consequently, it is unclear to what extent normal expression levels participate in regulation of currents and what the nature of the competition (or not) with CaM is. Additional approaches to clarify these points are suggested by the reviewers.
>
> 2\) The immunostaining in Figure 1 of stac expression in cardiac neurons is not convincing. The reviewers suggest either removal of these data or a more extensive validation of the antibodies and/or other means of verifying the signal.
>
> 3\) A number of discrepancies with the published literature were noted. These should be acknowledged and discussed, and where possible, resolutions proposed.
>
> 4\) The caliber of the data is high but the highly dramatic, hyperbolic language detracts from the overall quality of the manuscript. While some stylistic freedom is appropriate, it must not interfere with accuracy and readability. A few specific sentences are noted in the reviews, but the full manuscript should be revised substantially with this idea in mind.
>
> The basis for these comments, in the reviewers\' words, is included below, under \"Major Comments\" to facilitate the revision. Title: It is not clear that the prevention of CaM modulation of channels by stac is meaningfully described by the word \"shunt.\" Possibly a more straightforward work like \"prevent\" or \"interferes with\" would be more appropriate.

We thank the reviewers for this suggestion. The revised title replaces the word shunt with prevent.

Major comments (in the reviewers\' words; explaining basis for the essential revisions requested):

> 1\) Interpretations from overexpression. A general issue concerning the significance is that the key results in how stac proteins modify behavior of calcium channels are all with over-expression of stac, and there is no evidence that there is any \"tuning\" from this mechanism physiologically (in stark contrast to previous data with stac3 in skeletal muscle, where the physiological relevance is quite clear). Previous studies in both heart and neurons show prominent calcium-dependent inactivation, giving little reason to think that stac inhibition of this effect is important. The author\'s experiments here disrupting the interaction also suggest little or no physiological significance in cardiac muscle. An RNAi or knock-out approach would be better suited for testing physiological relevance for native Ca~v~1.2 or Ca~v~1.3 channels.
>
> Also, the authors conclude that STAC doesn\'t compete with CaM to suppress CDI, a mechanism apparently contrast to the \"competition-based\" mechanism implicated by Campiglio et al., 2018. While the multiple experiments in this manuscript do suggest that the authors\' model is more convincing, a major evidence the authors used to \"explicitly rule out\" that a displacement of CaM binding by STAC is necessary for CDI suppression is by fusing CaM to Ca~V~\'s C-terminus to increase local CaM concentration (Figure 3F-I). However, such a fusion still can\'t rule out that over-expressing STAC (as done in the paper) displaces CaM\'s binding to the site. One way to solve this problem is perhaps by directly monitor CaM binding with and without STAC. An easier, though less direct, experiment is perhaps to over-express CaM (as done in the single channel recordings in Figure 4) and to test whether STAC still eliminates CDI when CaM binding is presumably saturated.

We agree with the reviewers that mammalian knockout models of stac1 and stac2 would be powerful approaches to dissect the contribution of this modulatory mechanism to cardiac and neuronal function. However, to the best of our knowledge, there are no such models currently available and generation of one would be outside the scope of the present manuscript. For cardiac myocytes, two complexities further obscure analysis of stac modulation of Ca~V~ channels. First, the primary consequence of a reduction in Ca^2+^ channel inactivation is a prolongation of the phase 2 of the action potential. However, as mice exhibit minimal phase 2, murine models can be limiting in studying consequences of deficits in Ca~V~ inactivation. We chose freshly dissociated guinea pig models for pipette dialysis of U-motif peptides for this reason. Second, cultures of cardiac myocytes from guinea pig (and other organisms) de-differentiate within 24-48 hrs, resulting in marked changes in gene expression and a loss of channel modulation (e.g. β-adrenergic effect). This short time-window limits the practicality of approaches such as RNAi suppression. Given these limitations, we believe that the suggested experiments would be an exciting follow up study. Instead, we here focus on establishing a unified mechanistic framework for stac modulation of Ca~V~ channels and, in so doing, set the stage for subsequent in depth physiological analysis.

To ascertain stac levels necessary for physiological modulation, we undertook a live-cell FRET 2-hybrid assay to estimate holo-channel affinity for stac. We co-expressed YFP-tagged Ca~V~1.3 with CFP-tagged stac3 and measured FRET efficiencies from individual cells. Thus probed, we obtained an effective holochannel affinity of *K*~d,EFF~ = 1458 ± 251 *D*~free~ units \~ 47 nM. By comparison, similar holochannel analysis of CaM binding revealed *K*~d,EFF~ = 700 *D*~free~ units \~ 22 nM (Yang et al., 2014). Given this nanomolar affinity estimate, our expectation is that even low concentrations of stac would suffice to elicit functional modulation. Moreover, small changes in Ca~V~1 CDI elicits marked changes in cardiac action potential waveform suggesting that low levels of stac may be functionally important. These findings are shown in Figure 2.

In skeletal muscle where endogenous stac is very high (\~ μM range), the vast majority of channels would already be stac-bound and therefore insensitive to any fluctuations. By contrast, if ambient stac levels were in the nanomolar range, then even small fluctuations would tune baseline *P*~O~ and CDI. Recent work shows that the transcription factor NFAT binds to an upstream promoter region of stac2 gene and upregulates stac2 expression in osteoclasts (Jeong et al., 2018) and during hypoxic conditions in neural stem cells (Moreno et al., 2015). As NFAT signaling is upregulated during pathological cardiac hypertrophy, such conditions may also enhance stac expression.

The reviewers further raise an important concern regarding the nature of interplay between stac and CaM in modulating Ca~V~1. Though experiments using tethered CaM demonstrates that stac is capable of inhibiting CDI despite the overwhelming local concentration, it is possible that stac may yet displace CaM from its interaction site. To address this concern, we used FRET 2-hybrid assay to monitor CaM binding to its primary interface for Ca~V~1.3, the CI domain, both in the presence and absence of stac. Figure 3 shows robust baseline interaction of CFP-tagged CaM to YFP-tagged Ca~V~1.3 CI with a relative dissociation constant, *K*~d,EFF~ \~ 4000 ± 291 *D*~free~ units. If stac competes with CaM for a common interface, then the relative affinity would be reduced yielding a larger value for *K*~d,EFF~. Indeed, co-expression of untagged CaM~1234~ with aforementioned FRET pairs resulted in \~11-fold reduction in apparent affinity, with *K*~d,EFF~ = 47153 ± 4815 *D*~free~ units. By contrast, co-expression of untagged-stac3 did not appreciably perturb CI-CaM interaction with *K*~d,EFF~ = 4182 ± 330. These results demonstrate that stac does not displace CaM from its binding interface. These results have been added to Figure 3.

In addition to the FRET experiments, we also co-expressed Ca~V~1.3~S~ with both CaM and stac2 as suggested by the reviewers. This maneuver also showed a reduction in CDI confirming that stac eliminates CDI even when CaM binding is saturated. The data is shown in Figure 3---figure supplement 2G.

> 2\) Immunostaining. A potentially novel result is the immuno evidence for stac2 in cardiac muscle. Previous work concluded stac3 is expressed in skeletal muscle and stac1 and stac2 in neurons, with no clear expression of any in cardiac muscle. But here the staining for stac2 is weak and there is no validation of the antibody, so this is very weak evidence -especially since the disruption experiment suggests no basal modulation that might suggest endogenous stac expression. Everyone who has worked with antibodies knows how easy it is to get weak off-target staining. The title of Figure 1 \"Stac2 is differentially expressed in cardiac myocytes and neurons\" is also somewhat misleading, as the experiments don\'t examine stac2\'s expression in neurons and the immunostaining data is not quantitative.

We thank the reviewers for this suggestion.

To assess our ability to identify stac2 in immunostaining experiments, we undertook quantitative analysis of fluorescence intensities from confocal images of individual HEK293 cells expressing recombinant stac1-3 isoforms and probed via stac1 (top row) and stac2 (bottom row) antibodies. Black line in Figure 6---figure supplement 1B shows the distribution of fluorescence intensities from \~ 80 untransfected cells probed using anti-stac1 (top) with mean fluorescence intensities of F- = 218 ± 1.85 (s.e.m) a.u. HEK293 cells expressing recombinant stac1 when probed with anti-stac1 revealed a population of cells with enhanced fluorescence intensity with mean F- = 507 ± 77.63 (s.e.m) a.u. By comparison, fluorescence intensity distributions of HEK293 expressing recombinant stac2 or stac3 probed with anti-stac1 were indistinguishable from the distribution obtained for untransfected cells. In like manner, probing untransfected HEK293 cells with anti-stac2 antibody revealed minimal baseline staining with mean fluorescence intensity of F- = 266.8 ± 3.46. Exogenous expression of stac2 reveals a population of cells with enhanced fluorescence and mean fluorescence intensity, F-= 822.05 ± 143.9. By contrast, anti-stac2 labeling of cells expressing stac1 and stac3 revealed low fluorescence intensities comparable to the distribution for untransfected cells. These findings highlight the ability of the two antibodies to detect stac1 and stac2 respectively. Analysis of aGPVM revealed endogenous stac2 but not stac1.

As an alternative approach, we used western blot analysis to probe the presence of endogenous stac2 in cardiac myocytes. Analysis of untransfected HEK293 cells showed no signal when probed with stac2 antibody. However, analysis of cell lysates from HEK293 transfected with stac2 shows \~ 50 kDa band corresponding to stac2 (m.w. 47 kDa). Similarly, analysis of lysates from freshly dissociated cardiac myocytes show a similar-sized band as with stac2-transfected HEK cells.

> 3\) Relation to other work. The authors report several interesting findings in this paper. First, they found that all the STACs (STAC1-3) can abolish/reduce the calmodulin (CaM)-mediated CDI of L-type (Ca~V~1 sub-family) Ca~V~s (a finding also recently reported by other groups, e.g. Polster et al., 2015, Campiglio et al., 2018). Second, the authors used the FRET protein-interaction assay and found that STAC3 interacts with the proximal Ca^2+^-inactivating (PCI) segment of the Ca^2+^-inactivating (CI) module in the C-terminus of Ca~V~1.3, but not with the other segments, including the IQ motif immediately C-terminal to the PCI and the II/III loop previously found by others to interact with STACs in the Ca~V~1.1 (Yuen et al., 2017, Polster et al., 2018) or Ca~V~1.2 (Campiglio et al., 2018). Intriguingly, the authors found that a short \"linker\" between the C1 and the SH3 regions on STAC is required for STAC\'s suppression of CDI, and infusion of a U-motif peptide derived from this linker region is sufficient to remove CDI. This finding again is apparently contrast with a previous conclusion by others that the C1 domain is the major CDI-slowing determinant.
>
> Mechanistically, the authors conclude that STACs allosterically control CDI and \"lock\" the channel into a high opening probability state, a mechanism contrast to a previously proposed one by which STAC competes with CaM. Interestingly, the authors also discovered that the regulation of Na~V~\'s CDI by FGF has a structural requirement analogous to that of the regulation of Ca~V~s by STACs. Perhaps the most remarkable finding in the paper is that the authors were able to introduce an artificial Mona SH3-binding sequence in the PCI region to confer complete CDI inhibition by Mona SH3, a protein that doesn\'t affect the wild-type Ca~V~. Overall, there are many apparent \"discrepancies\" between the current paper and the two PNAS papers (Yuen et al., 2017, Campiglio et al., 2018), ranging from the STAC binding sites on Ca~V~s (PCI in this paper vs. the IQ motif and II/III loop in the others), and the important segment on STAC (linker vs. C1) to the mechanism (allosteric vs. competitive). The authors might want to elaborate the differences and provide potential explanations.

We thank the reviewers for this excellent suggestion. We could not include an in-depth discussion on apparent discrepancies in our original submission as multiple papers here were only published after our initial submission (e.g. Campiglio et al., 2018 and Polster et al., 2018). The revised Discussion section now includes a subsection entitled "Relationship to prior studies" to compare and contrast these findings.

> 4\) Writing. A comment on style: The authors use a prose style with so many dramatic statements and intensifying adjectives that it will likely irritate and even alienate some readers. In my opinion, a more sober presentation in a standard style that lets the results speak for themselves is more effective. Insisting on telling the reader how important the results are (like repeatedly using \"Remarkably\" for results that seem very straightforward, like seeing similar effects on Ca~v~1.4 as for Ca~v~1.1, Ca~v~1.2, and Ca~v~1.3) can make the reader think that he or she is receiving a sales pitch rather than being told results. There are too many examples of over-dramatic language to list but one was the statement that stac and fhf exert \"orthogonal\" control because one interacts with calcium channels and one with sodium channels. Calmodulin interacts with dozens if not hundreds of proteins, and of course there are ways that the interactions are regulated differently -- is each one of these an orthogonal dimension? I had a similar reaction to sentences like \"Synergistic analysis of the two proteins delineate mechanisms that confer personalized modulation and inform upon physiological consequences\" and \"Repurposing this modulatory principle furnishes a general strategy for engineering synthetic modulators that patently switch CaV and NaV channel feedback.\" (These sentences lie between a lack of clear meaning and inaccuracy.)

We apologize for our enthusiasm. We have revised the manuscript accordingly.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some important issues that need to be addressed, as outlined below:
>
> One reviewer (whose comments are included verbatim below) identified some inconsistencies in the match between figure panels cited in the text and in the figures, and also noted that the control plots in the last two supplementary figures (Figure 7---figure supplement 1 and Figure 8---figure supplement 1) appear to be identical, but the duplication (if these are indeed duplicates) is neither justified nor indicated in the legends. The same panel appears to be duplicated in Figure 1---figure supplement 1 and Figure 3---figure supplement 1, although in the latter it is labeled as N=6 instead of N=9 as in the other three panels. These issues raise concern about the care with which the manuscript was assembled and presented.
>
> Before a final decision is rendered, please ensure (1) that the correct data and figure panels are present throughout the manuscript, (2) that they are called correctly, (3) that any duplication of panels to facilitate comparison is clearly indicated as such (with appropriate justification for a common control group), and (4) that there are no other related errors. In your revision, please clearly indicate the corrections that have been made.

We thank all reviewers and editors for the careful evaluation of our manuscript. We sincerely apologize for the errors and inconsistencies in our text and figures. These were inadvertent and have been rectified. The *n* values for each figure were verified/corrected, and the figures are also now referenced correctly.

Figure duplications are elaborated below:

1\) Figure 6C control bar is duplicated from Figure 1B. The duplication is stated explicitly and highlighted in yellow.

Justification for duplication *--* in this experiment, we pipette dialyze U-motif into HEK293 cells transfected with Ca~V~1.2 to probe changes in CDI. The appropriate control relation here would be Ca~V~1.2 without the peptide dialysate, which is equivalent to Ca~V~1.2 at baseline. As control experiments in Figure 1A-B also deduced Ca~V~1.2 CDI at baseline (i.e. without stac), we pooled the datasets together.

In the previous submission, Figure 6---figure supplement 2B was duplicated from Figure 1---figure supplement 1A. In the revised we have removed this duplication to minimize any confusion.

2\) Control bars in Figures 1D, 7E, and 8C are duplicated to facilitate comparison and for symmetry.

Justification for duplication *--* Figure 1D compares CDI of Ca~V~1.3 in the presence of stac to baseline levels. Figure 7E compares CDI of Ca~V~1.3 with the addition of fhf1 to baseline levels, and Figure 8C compares CDI of Ca~V~1.3 with the addition of Mona SH3 to baseline levels. In all three cases, as the appropriate control relation would be the baseline CDI of Ca~V~1.3 under endogenous levels of CaM and without the addition regulatory protein being tested, we duplicated the control bars.

In the previous submission, Control *r*~300~ relations in Figure 1---figure supplement 1B, Figure 3---figure supplement 1B, Figure 7---figure supplement 7B, and Figure 8---figure supplement 1B were duplicates. We have removed these duplications to avoid any confusion.

3\) Control CDI~max~ bar in Figure 7C is duplicated from Figure 1N to facilitate comparison.

Justification for duplication *--* in Figure 1, we compare CDI of Na~V~1.4 at baseline with stac2 overexpression. Similarly, in Figure 7, we compare CDI of Na~V~1.4 at baseline with fhf1b overexpression. The duplication here occurs as the control relation in both cases is CDI of Na~V~1.4 at baseline with addition of an auxiliary regulatory protein.

In the previous submission, the CDI -- Ca relationship for Na~V~1.4 at baseline was duplicated in Figure 7---figure supplement 1B from Figure 1---figure supplement 1G. This has been removed from the revised version to minimize confusion.

4\) Control traces in Figure 3---figure supplement 1C was duplicated from Figure 3A to preserve symmetry of the figure and for ease of comparison. We left this duplication intact.

Justification for duplication -- the supplementary figure like the main text figure shows that CaM fusion protects from dominant negative CaM, a competitive inhibitor of CDI. Figure 3---figure supplement 1C shows exemplar traces in the presence and absence of dominant negative CaM to be able to visually compare kinetics of inactivation. The steady state values are reported in panel D.

> Reviewer comments:
>
> The revision generally addresses the main issues raised on the original version. The data are extensive and comprise a very comprehensive picture of the molecular interactions with the multiple STAC proteins with multiple calcium channels. It is still unproven that the STAC interaction functions physiologically to \"tune\" Ca-dependent channel inactivation, but the authors make a good point that testing this via RNAi would be technically challenging given current experimental systems and making knock-out mice would be a major project. The fact that STAC proteins are heavily expressed in the brain gives some credence to the idea that they could be functionally important in neurons, or knock-outs.
>
> The authors need to proof-read the manuscript more carefully. The reviewer copy was hard to read, as it consisted of a pdf incorporating cross-outs and additions, which made spotting errors difficult. However, it is obvious that not all changes in re-numbering figure references were done correctly (e.g. in the first paragraph of the subsection "Stac selectively suppresses Ca^2+^-feedback of Ca~V~1 channels", Figure 2A should now be 1A, and in the second paragraph of the subsection "Stac interacts with CaV1 CI module to elicit CDI suppression", Figure 3B should be 2B).
>
> Also the fact that the figures were not numbered made the reviewing process more difficult than was necessary. Also, at the end of the manuscript there are supplementary figures that are exact duplicates.

We thank the reviewer for these comments and for the careful reading of our manuscript. We also apologize for the confusion. We realized *eLife* requested that we incorporate track changes for resubmission only after we had made substantial textual changes. As such, we attempted to reincorporate our changes that then led to errors. We have corrected these in the revision and have also removed track changes here. We are not sure how to number the figures as we had to submit these separately as individual image files.
